Selected Member Publications

Mowery YM, Luke JJ. NETosis Impact on Tumor Biology, Radiation, and Systemic Therapy Resistance. Clin Cancer Res. 2024-07-15; doi: 10.1158/1078-0432.CCR-24-1363. nihFormattedCitation: Mowery YM, Luke JJ. NETosis Impact on Tumor Biology, Radiation, and Systemic Therapy Resistance. Clin Cancer Res. 2024;.. PubMed PMID: 39007757.
van der Burg SH, Lotze MT. Perspectives from the leadership of Journal for ImmunoTherapy of Cancer. J Immunother Cancer. 2024-06-19;12(6): doi: 10.1136/jitc-2024-009661. nihFormattedCitation: van der Burg SH, Lotze MT. Perspectives from the leadership of Journal for ImmunoTherapy of Cancer. J Immunother Cancer. 2024;12(6). PMCID: PMC11191768.. PubMed PMID: 38901880; PMCID: PMC11191768.
Shao L, Srivastava R, Delgoffe GM, Thorne SH, Sarkar SN. An IRF2-Expressing Oncolytic Virus Changes the Susceptibility of Tumor Cells to Antitumor T cells and Promotes Tumor Clearance. Cancer Immunol Res. 2024-06-04; doi: 10.1158/2326-6066.CIR-23-0573. nihFormattedCitation: Shao L, Srivastava R, Delgoffe GM, Thorne SH, Sarkar SN. An IRF2-Expressing Oncolytic Virus Changes the Susceptibility of Tumor Cells to Antitumor T cells and Promotes Tumor Clearance. Cancer Immunol Res. 2024;. PMCID: PMC11150089.. PubMed PMID: 38517470; PMCID: PMC11150089.
Lee AH, Randhawa SK, Meisel M. Dietary commensal wrestles iron from tumor microenvironment to activate antitumoral macrophages. Cancer Res. 2024-06-04; doi: 10.1158/0008-5472.CAN-24-1833. nihFormattedCitation: Lee AH, Randhawa SK, Meisel M. Dietary commensal wrestles iron from tumor microenvironment to activate antitumoral macrophages. Cancer Res. 2024;.. PubMed PMID: 38832925.
Maleki Vareki S, Davar D. Identification of dynamic microbiota signatures in patients with melanoma receiving ICIs: opportunities and challenges. Nat Rev Clin Oncol. 2024-06-01; doi: 10.1038/s41571-024-00882-2. nihFormattedCitation: Maleki Vareki S, Davar D. Identification of dynamic microbiota signatures in patients with melanoma receiving ICIs: opportunities and challenges. Nat Rev Clin Oncol. 2024;.. PubMed PMID: 38509333.
Butterfield LH, Najjar YG. Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations. Nat Rev Immunol. 2024-06-01; doi: 10.1038/s41577-023-00973-8. nihFormattedCitation: Butterfield LH, Najjar YG. Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations. Nat Rev Immunol. 2024;.. PubMed PMID: 38057451.
Baessler A, Vignali DAA. T Cell Exhaustion. Annu Rev Immunol. 2024-06-01; doi: 10.1146/annurev-immunol-090222-110914. nihFormattedCitation: Baessler A, Vignali DAA. T Cell Exhaustion. Annu Rev Immunol. 2024;.. PubMed PMID: 38166256.
Luke JJ, Ascierto PA, Khattak MA, de la Cruz Merino L, Del Vecchio M, Rutkowski P, Spagnolo F, Mackiewicz J, Chiarion-Sileni V, Kirkwood JM, Robert C, Grob JJ, de Galitiis F, Schadendorf D, Carlino MS, Wu XL, Fukunaga-Kalabis M, Krepler C, Eggermont AMM, Long GV. Pembrolizumab Versus Placebo as Adjuvant Therapy in Resected Stage IIB or IIC Melanoma: Final Analysis of Distant Metastasis-Free Survival in the Phase III KEYNOTE-716 Study. J Clin Oncol. 2024-05-10;JCO2302355. doi: 10.1200/JCO.23.02355. nihFormattedCitation: Luke JJ, Ascierto PA, Khattak MA, de la Cruz Merino L, Del Vecchio M, Rutkowski P, Spagnolo F, Mackiewicz J, Chiarion-Sileni V, Kirkwood JM, Robert C, Grob JJ, de Galitiis F, Schadendorf D, Carlino MS, Wu XL, Fukunaga-Kalabis M, Krepler C, Eggermont AMM, Long GV. Pembrolizumab Versus Placebo as Adjuvant Therapy in Resected Stage IIB or IIC Melanoma: Final Analysis of Distant Metastasis-Free Survival in the Phase III KEYNOTE-716 Study. J Clin Oncol. 2024;:JCO2302355. PMCID: PMC11095869.. PubMed PMID: 38452313; PMCID: PMC11095869.
Mangla A, Lee C, Mirsky MM, Wang M, Rothermel LD, Hoehn R, Bordeaux JS, Carrol BT, Theuner J, Li S, Fu P, Kirkwood JM. Neoadjuvant Dual Checkpoint Inhibitors vs Anti-PD1 Therapy in High-Risk Resectable Melanoma: A Pooled Analysis. JAMA Oncol. 2024-05-01; doi: 10.1001/jamaoncol.2023.7333. nihFormattedCitation: Mangla A, Lee C, Mirsky MM, Wang M, Rothermel LD, Hoehn R, Bordeaux JS, Carrol BT, Theuner J, Li S, Fu P, Kirkwood JM. Neoadjuvant Dual Checkpoint Inhibitors vs Anti-PD1 Therapy in High-Risk Resectable Melanoma: A Pooled Analysis. JAMA Oncol. 2024;. PMCID: PMC10979364.. PubMed PMID: 38546551; PMCID: PMC10979364.
Vignali PDA, Luke JJ. Unraveling the therapeutic benefit of sequenced chemo-immunotherapy. Clin Cancer Res. 2024-05-01; doi: 10.1158/1078-0432.CCR-23-3736. nihFormattedCitation: Vignali PDA, Luke JJ. Unraveling the therapeutic benefit of sequenced chemo-immunotherapy. Clin Cancer Res. 2024;. PMCID: PMC11062819.. PubMed PMID: 38372597; PMCID: PMC11062819.
Luke JJ, Davar D, Andtbacka RH, Bhardwaj N, Brody JD, Chesney J, Coffin R, de Baere T, de Gruijl TD, Fury M, Goldmacher G, Harrington KJ, Kaufman H, Kelly CM, Khilnani AD, Liu K, Loi S, Long GV, Melero I, Middleton M, Neyns B, Pinato DJ, Sheth RA, Solomon SB, Szapary P, Marabelle A. Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): from premalignant to metastatic disease. J Immunother Cancer. 2024-04-18;12(4): doi: 10.1136/jitc-2023-008378. nihFormattedCitation: Luke JJ, Davar D, Andtbacka RH, Bhardwaj N, Brody JD, Chesney J, Coffin R, de Baere T, de Gruijl TD, Fury M, Goldmacher G, Harrington KJ, Kaufman H, Kelly CM, Khilnani AD, Liu K, Loi S, Long GV, Melero I, Middleton M, Neyns B, Pinato DJ, Sheth RA, Solomon SB, Szapary P, Marabelle A. Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): from premalignant to metastatic disease. J Immunother Cancer. 2024;12(4). PMCID: PMC11029323.. PubMed PMID: 38641350; PMCID: PMC11029323.
Leonard-Murali S, Bhaskarla C, Yadav GS, Maurya SK, Galiveti CR, Tobin JA, Kann RJ, Ashwat E, Murphy PS, Chakka AB, Soman V, Cantalupo PG, Zhuo X, Vyas G, Kozak DL, Kelly LM, Smith E, Chandran UR, Hsu YS, Kammula US. Uveal melanoma immunogenomics predict immunotherapy resistance and susceptibility. Nat Commun. 2024-04-16;15(1):2863. doi: 10.1038/s41467-024-46906-4. nihFormattedCitation: Leonard-Murali S, Bhaskarla C, Yadav GS, Maurya SK, Galiveti CR, Tobin JA, Kann RJ, Ashwat E, Murphy PS, Chakka AB, Soman V, Cantalupo PG, Zhuo X, Vyas G, Kozak DL, Kelly LM, Smith E, Chandran UR, Hsu YS, Kammula US. Uveal melanoma immunogenomics predict immunotherapy resistance and susceptibility. Nat Commun. 2024;15(1):2863. PMCID: PMC11021475.. PubMed PMID: 38627362; PMCID: PMC11021475.
Sitc S, Lotze MT, Cottrell T, Bifulco C, Chow L, Cope L, Gnjatic S, Maecker HT, Yeong Poh Shen J. SITC Clinical Immuno-Oncology Network (SCION) commentary on measurement and interpretation of essential biomarkers in early clinical trials. J Immunother Cancer. 2024-03-21;12(3): doi: 10.1136/jitc-2023-008655. nihFormattedCitation: Sitc S, Lotze MT, Cottrell T, Bifulco C, Chow L, Cope L, Gnjatic S, Maecker HT, Yeong Poh Shen J. SITC Clinical Immuno-Oncology Network (SCION) commentary on measurement and interpretation of essential biomarkers in early clinical trials. J Immunother Cancer. 2024;12(3). PMCID: PMC10961490.. PubMed PMID: 38519056; PMCID: PMC10961490.
Wilfahrt D, Delgoffe GM. Metabolic waypoints during T cell differentiation. Nat Immunol. 2024-02-01; doi: 10.1038/s41590-023-01733-5. nihFormattedCitation: Wilfahrt D, Delgoffe GM. Metabolic waypoints during T cell differentiation. Nat Immunol. 2024;.. PubMed PMID: 38238609.
Casillo SM, Gatesman TA, Chilukuri A, Varadharajan S, Johnson BJ, David Premkumar DR, Jane EP, Plute TJ, Koncar RF, Stanton AJ, Biagi-Junior CAO, Barber CS, Halbert ME, Golbourn BJ, Halligan K, Cruz AF, Mansi NM, Cheney A, Mullett SJ, Land CV, Perez JL, Myers MI, Agrawal N, Michel JJ, Chang YF, Vaske OM, MichaelRaj A, Lieberman FS, Felker J, Shiva S, Bertrand KC, Amankulor N, Hadjipanayis CG, Abdullah KG, Zinn PO, Friedlander RM, Abel TJ, Nazarian J, Venneti S, Filbin MG, Gelhaus SL, Mack SC, Pollack IF, Agnihotri S. An ERK5-PFKFB3 axis regulates glycolysis and represents a therapeutic vulnerability in pediatric diffuse midline glioma. Cell Rep. 2024-01-23;43(1):113557. doi: 10.1016/j.celrep.2023.113557. nihFormattedCitation: Casillo SM, Gatesman TA, Chilukuri A, Varadharajan S, Johnson BJ, David Premkumar DR, Jane EP, Plute TJ, Koncar RF, Stanton AJ, Biagi-Junior CAO, Barber CS, Halbert ME, Golbourn BJ, Halligan K, Cruz AF, Mansi NM, Cheney A, Mullett SJ, Land CV, Perez JL, Myers MI, Agrawal N, Michel JJ, Chang YF, Vaske OM, MichaelRaj A, Lieberman FS, Felker J, Shiva S, Bertrand KC, Amankulor N, Hadjipanayis CG, Abdullah KG, Zinn PO, Friedlander RM, Abel TJ, Nazarian J, Venneti S, Filbin MG, Gelhaus SL, Mack SC, Pollack IF, Agnihotri S. An ERK5-PFKFB3 axis regulates glycolysis and represents a therapeutic vulnerability in pediatric diffuse midline glioma. Cell Rep. 2024;43(1):113557.. PubMed PMID: 38113141.
Silk AW, Davar D. Tumor-Associated Macrophages in Merkel Cell Carcinoma: Old Balances, New Checks. Clin Cancer Res. 2024-01-17;OF1-OF3. doi: 10.1158/1078-0432.CCR-23-3320. nihFormattedCitation: Silk AW, Davar D. Tumor-Associated Macrophages in Merkel Cell Carcinoma: Old Balances, New Checks. Clin Cancer Res. 2024;:OF1-OF3.. PubMed PMID: 38230965.
Jana JA, Overacre-Delgoffe AE. You are the tumor queen, microbiome fiend, IL-17. Immunity. 2024-01-09;57(1):11-13. doi: 10.1016/j.immuni.2023.12.011. nihFormattedCitation: Jana JA, Overacre-Delgoffe AE. You are the tumor queen, microbiome fiend, IL-17. Immunity. 2024;57(1):11-13.. PubMed PMID: 38198848.
Wu RC, Luke JJ. Uncovering the potential of CD40 agonism to enhance immune-checkpoint blockade. Clin Cancer Res. 2024-01-05; doi: 10.1158/1078-0432.CCR-23-2437. nihFormattedCitation: Wu RC, Luke JJ. Uncovering the potential of CD40 agonism to enhance immune-checkpoint blockade. Clin Cancer Res. 2024;. PMCID: PMC10842335.. PubMed PMID: 37870487; PMCID: PMC10842335.
Silk AW, Davar D. Tumor-associated Macrophages in Merkel Cell Carcinoma: Old Balances, New Checks. Clin Cancer Res. 2024-01-03; doi: 10.1158/1078-0432.CCR-23-3320. nihFormattedCitation: Silk AW, Davar D. Tumor-associated Macrophages in Merkel Cell Carcinoma: Old Balances, New Checks. Clin Cancer Res. 2024;.. PubMed PMID: 38170200.
Tang D, Kang R, Zeh HJ, Lotze MT. The multifunctional protein HMGB1: 50 years of discovery. Nat Rev Immunol. 2023-12-01; doi: 10.1038/s41577-023-00894-6. nihFormattedCitation: Tang D, Kang R, Zeh HJ, Lotze MT. The multifunctional protein HMGB1: 50 years of discovery. Nat Rev Immunol. 2023;.. PubMed PMID: 37322174.
Kirkwood J, Del Vecchio M, Weber J, Hoeller C, Grob JJ, Mohr P, Loquai C, Dutriaux C, Chiarion-Sileni V, Mackiewicz J, Rutkowski P, Arenberger P, Quereux G, Meniawy TM, Ascierto PA, Menzies AM, Durani P, Lobo M, Campigotto F, Gastman B, Long GV. Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial. Nat Med. 2023-11-01; doi: 10.1038/s41591-023-02583-2. nihFormattedCitation: Kirkwood J, Del Vecchio M, Weber J, Hoeller C, Grob JJ, Mohr P, Loquai C, Dutriaux C, Chiarion-Sileni V, Mackiewicz J, Rutkowski P, Arenberger P, Quereux G, Meniawy TM, Ascierto PA, Menzies AM, Durani P, Lobo M, Campigotto F, Gastman B, Long GV. Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial. Nat Med. 2023;. PMCID: PMC10667090.. PubMed PMID: 37845511; PMCID: PMC10667090.
Luke JJ, Patel MR, Blumenschein GR, Hamilton E, Chmielowski B, Ulahannan SV, Connolly RM, Santa-Maria CA, Wang J, Bahadur SW, Weickhardt A, Asch AS, Mallesara G, Clingan P, Dlugosz-Danecka M, Tomaszewska-Kiecana M, Pylypenko H, Hamad N, Kindler HL, Sumrow BJ, Kaminker P, Chen FZ, Zhang X, Shah K, Smith DH, De Costa A, Li J, Li H, Sun J, Moore PA. The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial. Nat Med. 2023-11-01; doi: 10.1038/s41591-023-02593-0. nihFormattedCitation: Luke JJ, Patel MR, Blumenschein GR, Hamilton E, Chmielowski B, Ulahannan SV, Connolly RM, Santa-Maria CA, Wang J, Bahadur SW, Weickhardt A, Asch AS, Mallesara G, Clingan P, Dlugosz-Danecka M, Tomaszewska-Kiecana M, Pylypenko H, Hamad N, Kindler HL, Sumrow BJ, Kaminker P, Chen FZ, Zhang X, Shah K, Smith DH, De Costa A, Li J, Li H, Sun J, Moore PA. The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial. Nat Med. 2023;. PMCID: PMC10667103.. PubMed PMID: 37857711; PMCID: PMC10667103.
DePeaux K, Rivadeneira DB, Lontos K, Dean VG, Gunn WG, Watson MJ, Yao T, Wilfahrt D, Hinck C, Wieteska L, Thorne SH, Hinck AP, Delgoffe GM. An oncolytic virus-delivered TGFβ inhibitor overcomes the immunosuppressive tumor microenvironment. J Exp Med. 2023-10-02;220(10): doi: 10.1084/jem.20230053. nihFormattedCitation: DePeaux K, Rivadeneira DB, Lontos K, Dean VG, Gunn WG, Watson MJ, Yao T, Wilfahrt D, Hinck C, Wieteska L, Thorne SH, Hinck AP, Delgoffe GM. An oncolytic virus-delivered TGFβ inhibitor overcomes the immunosuppressive tumor microenvironment. J Exp Med. 2023;220(10). PMCID: PMC10407786.. PubMed PMID: 37552475; PMCID: PMC10407786.
Betof Warner A, Luke JJ. CD4+ TIL to the rescue of anti-PD-1 failure by targeting MHC-II. Clin Cancer Res. 2023-10-02; doi: 10.1158/1078-0432.CCR-23-1333. nihFormattedCitation: Betof Warner A, Luke JJ. CD4+ TIL to the rescue of anti-PD-1 failure by targeting MHC-II. Clin Cancer Res. 2023;. PMCID: PMC10592266.. PubMed PMID: 37534980; PMCID: PMC10592266.
Zhang X, Ferris L, Faries MB, Luke JJ. Debating Sentinel Lymph Node Biopsy for Melanoma in the Modern Adjuvant Era. J Clin Oncol. 2023-09-10;JCO2300255. doi: 10.1200/JCO.23.00255. nihFormattedCitation: Zhang X, Ferris L, Faries MB, Luke JJ. Debating Sentinel Lymph Node Biopsy for Melanoma in the Modern Adjuvant Era. J Clin Oncol. 2023;:JCO2300255. PMCID: PMC10852382.. PubMed PMID: 37410978; PMCID: PMC10852382.
Vashisht M, Ge H, John J, McKelvey HA, Chen J, Chen Z, Wang JH. TRAF2/3 deficient B cells resist DNA damage-induced apoptosis via NF-κB2/XIAP/cIAP2 axis and IAP antagonist sensitizes mutant lymphomas to chemotherapeutic drugs. Cell Death Dis. 2023-09-08;14(9):599. doi: 10.1038/s41419-023-06122-2. nihFormattedCitation: Vashisht M, Ge H, John J, McKelvey HA, Chen J, Chen Z, Wang JH. TRAF2/3 deficient B cells resist DNA damage-induced apoptosis via NF-κB2/XIAP/cIAP2 axis and IAP antagonist sensitizes mutant lymphomas to chemotherapeutic drugs. Cell Death Dis. 2023;14(9):599. PMCID: PMC10485046.. PubMed PMID: 37679334; PMCID: PMC10485046.
Aggarwal V, Workman CJ, Vignali DAA. LAG-3 as the third checkpoint inhibitor. Nat Immunol. 2023-09-01;24(9):1415-1422. doi: 10.1038/s41590-023-01569-z. nihFormattedCitation: Aggarwal V, Workman CJ, Vignali DAA. LAG-3 as the third checkpoint inhibitor. Nat Immunol. 2023;24(9):1415-1422. PMCID: PMC11144386.. PubMed PMID: 37488429; PMCID: PMC11144386.
Augustin RC, Luke JJ. PD-1 Monotherapy Reigns Supreme in Adjuvant Melanoma…But for How Long? Clin Cancer Res. 2023-09-01;29(17):3253-3255. doi: 10.1158/1078-0432.CCR-23-1194. nihFormattedCitation: Augustin RC, Luke JJ. PD-1 Monotherapy Reigns Supreme in Adjuvant Melanoma…But for How Long? Clin Cancer Res. 2023;29(17):3253-3255. PMCID: PMC10527539.. PubMed PMID: 37378689; PMCID: PMC10527539.
Medina Sanchez L, Siller M, Zeng Y, Brigleb PH, Sangani KA, Soto AS, Engl C, Laughlin CR, Rana M, Van Der Kraak L, Pandey SP, Bender MJ, Fitzgerald B, Hedden L, Fiske K, Taylor GM, Wright AP, Mehta ID, Rahman SA, Galipeau HJ, Mullett SJ, Gelhaus SL, Watkins SC, Bercik P, Nice TJ, Jabri B, Meisel M, Das J, Dermody TS, Verdú EF, Hinterleitner R. The gut protist Tritrichomonas arnold restrains virus-mediated loss of oral tolerance by modulating dietary antigen-presenting dendritic cells. Immunity. 2023-08-08;56(8):1862-1875.e9. doi: 10.1016/j.immuni.2023.06.022. nihFormattedCitation: Medina Sanchez L, Siller M, Zeng Y, Brigleb PH, Sangani KA, Soto AS, Engl C, Laughlin CR, Rana M, Van Der Kraak L, Pandey SP, Bender MJ, Fitzgerald B, Hedden L, Fiske K, Taylor GM, Wright AP, Mehta ID, Rahman SA, Galipeau HJ, Mullett SJ, Gelhaus SL, Watkins SC, Bercik P, Nice TJ, Jabri B, Meisel M, Das J, Dermody TS, Verdú EF, Hinterleitner R. The gut protist Tritrichomonas arnold restrains virus-mediated loss of oral tolerance by modulating dietary antigen-presenting dendritic cells. Immunity. 2023;56(8):1862-1875.e9. PMCID: PMC10529081.. PubMed PMID: 37478853; PMCID: PMC10529081.
Smithy JW, Luke JJ. CD16+ Macrophages: An Emerging Biomarker for Combined CTLA-4 and PD-1 Blockade. Clin Cancer Res. 2023-07-05;29(13):2345-2347. doi: 10.1158/1078-0432.CCR-23-0490. nihFormattedCitation: Smithy JW, Luke JJ. CD16+ Macrophages: An Emerging Biomarker for Combined CTLA-4 and PD-1 Blockade. Clin Cancer Res. 2023;29(13):2345-2347. PMCID: PMC10330271.. PubMed PMID: 37097465; PMCID: PMC10330271.
Luke JJ, Piha-Paul SA, Medina T, Verschraegen CF, Varterasian M, Brennan AM, Riese RJ, Sokolovska A, Strauss J, Hava DL, Janku F. Phase I Study of SYNB1891, an Engineered E. coli Nissle Strain Expressing STING Agonist, with and without Atezolizumab in Advanced Malignancies. Clin Cancer Res. 2023-07-05;29(13):2435-2444. doi: 10.1158/1078-0432.CCR-23-0118. nihFormattedCitation: Luke JJ, Piha-Paul SA, Medina T, Verschraegen CF, Varterasian M, Brennan AM, Riese RJ, Sokolovska A, Strauss J, Hava DL, Janku F. Phase I Study of SYNB1891, an Engineered E. coli Nissle Strain Expressing STING Agonist, with and without Atezolizumab in Advanced Malignancies. Clin Cancer Res. 2023;29(13):2435-2444. PMCID: PMC11225568.. PubMed PMID: 37227176; PMCID: PMC11225568.
Gottschalk RA. Signaling is the pathway to macrophage function. Trends Immunol. 2023-07-01;44(7):496-498. doi: 10.1016/j.it.2023.04.007. nihFormattedCitation: Gottschalk RA. Signaling is the pathway to macrophage function. Trends Immunol. 2023;44(7):496-498.. PubMed PMID: 37258361.
Kann BH, Likitlersuang J, Bontempi D, Ye Z, Aneja S, Bakst R, Kelly HR, Juliano AF, Payabvash S, Guenette JP, Uppaluri R, Margalit DN, Schoenfeld JD, Tishler RB, Haddad R, Aerts HJWL, Garcia JJ, Flamand Y, Subramaniam RM, Burtness BA, Ferris RL. Screening for extranodal extension in HPV-associated oropharyngeal carcinoma: evaluation of a CT-based deep learning algorithm in patient data from a multicentre, randomised de-escalation trial. Lancet Digit Health. 2023-06-01;5(6):e360-e369. doi: 10.1016/S2589-7500(23)00046-8. nihFormattedCitation: Kann BH, Likitlersuang J, Bontempi D, Ye Z, Aneja S, Bakst R, Kelly HR, Juliano AF, Payabvash S, Guenette JP, Uppaluri R, Margalit DN, Schoenfeld JD, Tishler RB, Haddad R, Aerts HJWL, Garcia JJ, Flamand Y, Subramaniam RM, Burtness BA, Ferris RL. Screening for extranodal extension in HPV-associated oropharyngeal carcinoma: evaluation of a CT-based deep learning algorithm in patient data from a multicentre, randomised de-escalation trial. Lancet Digit Health. 2023;5(6):e360-e369. PMCID: PMC10245380.. PubMed PMID: 37087370; PMCID: PMC10245380.
Korpics MC, Onderdonk BE, Dadey RE, Hara JH, Karapetyan L, Zha Y, Karrison TG, Olson AC, Fleming GF, Weichselbaum RR, Bao R, Chmura SJ, Luke JJ. Partial tumor irradiation plus pembrolizumab in treating large advanced solid tumor metastases. J Clin Invest. 2023-05-15;133(10): doi: 10.1172/JCI162260. nihFormattedCitation: Korpics MC, Onderdonk BE, Dadey RE, Hara JH, Karapetyan L, Zha Y, Karrison TG, Olson AC, Fleming GF, Weichselbaum RR, Bao R, Chmura SJ, Luke JJ. Partial tumor irradiation plus pembrolizumab in treating large advanced solid tumor metastases. J Clin Invest. 2023;133(10). PMCID: PMC10178837.. PubMed PMID: 37183819; PMCID: PMC10178837.
Luke JJ, Piha-Paul SA, Medina T, Verschraegen CF, Varterasian M, Brennan AM, Riese RJ, Sokolovska A, Strauss JF, Hava DL, Janku F. Phase I study of SYNB1891, an engineered E coli Nissle strain expressing STING agonist, with and without atezolizumab in advanced malignancies. Clin Cancer Res. 2023-05-09; doi: 10.1158/1078-0432.CCR-23-0118. nihFormattedCitation: Luke JJ, Piha-Paul SA, Medina T, Verschraegen CF, Varterasian M, Brennan AM, Riese RJ, Sokolovska A, Strauss JF, Hava DL, Janku F. Phase I study of SYNB1891, an engineered E coli Nissle strain expressing STING agonist, with and without atezolizumab in advanced malignancies. Clin Cancer Res. 2023;.. PubMed PMID: 37159185.
Ruffo E, Butchy AA, Tivon Y, So V, Kvorjak M, Parikh A, Adams EL, Miskov-Zivanov N, Finn OJ, Deiters A, Lohmueller J. Post-translational covalent assembly of CAR and synNotch receptors for programmable antigen targeting. Nat Commun. 2023-05-09;14(1):2463. doi: 10.1038/s41467-023-37863-5. nihFormattedCitation: Ruffo E, Butchy AA, Tivon Y, So V, Kvorjak M, Parikh A, Adams EL, Miskov-Zivanov N, Finn OJ, Deiters A, Lohmueller J. Post-translational covalent assembly of CAR and synNotch receptors for programmable antigen targeting. Nat Commun. 2023;14(1):2463. PMCID: PMC10169838.. PubMed PMID: 37160880; PMCID: PMC10169838.
Schoen RE, Boardman LA, Cruz-Correa M, Bansal A, Kastenberg D, Hur C, Dzubinski L, Kaufman SF, Rodriguez LM, Richmond E, Umar A, Szabo E, Salazar A, McKolanis J, Beatty P, Pai RK, Singhi AD, Jacqueline CM, Bao R, Diergaarde B, McMurray RP, Strand C, Foster NR, Zahrieh DM, Limburg PJ, Finn OJ. Randomized, Double-Blind, Placebo-Controlled Trial of MUC1 Peptide Vaccine for Prevention of Recurrent Colorectal Adenoma. Clin Cancer Res. 2023-05-01;29(9):1678-1688. doi: 10.1158/1078-0432.CCR-22-3168. nihFormattedCitation: Schoen RE, Boardman LA, Cruz-Correa M, Bansal A, Kastenberg D, Hur C, Dzubinski L, Kaufman SF, Rodriguez LM, Richmond E, Umar A, Szabo E, Salazar A, McKolanis J, Beatty P, Pai RK, Singhi AD, Jacqueline CM, Bao R, Diergaarde B, McMurray RP, Strand C, Foster NR, Zahrieh DM, Limburg PJ, Finn OJ. Randomized, Double-Blind, Placebo-Controlled Trial of MUC1 Peptide Vaccine for Prevention of Recurrent Colorectal Adenoma. Clin Cancer Res. 2023;29(9):1678-1688. PMCID: PMC10159922.. PubMed PMID: 36892581; PMCID: PMC10159922.
Bender MJ, McPherson AC, Phelps CM, Pandey SP, Laughlin CR, Shapira JH, Medina Sanchez L, Rana M, Richie TG, Mims TS, Gocher-Demske AM, Cervantes-Barragan L, Mullett SJ, Gelhaus SL, Bruno TC, Cannon N, McCulloch JA, Vignali DAA, Hinterleitner R, Joglekar AV, Pierre JF, Lee STM, Davar D, Zarour HM, Meisel M. Dietary tryptophan metabolite released by intratumoral Lactobacillus reuteri facilitates immune checkpoint inhibitor treatment. Cell. 2023-04-27;186(9):1846-1862.e26. doi: 10.1016/j.cell.2023.03.011. nihFormattedCitation: Bender MJ, McPherson AC, Phelps CM, Pandey SP, Laughlin CR, Shapira JH, Medina Sanchez L, Rana M, Richie TG, Mims TS, Gocher-Demske AM, Cervantes-Barragan L, Mullett SJ, Gelhaus SL, Bruno TC, Cannon N, McCulloch JA, Vignali DAA, Hinterleitner R, Joglekar AV, Pierre JF, Lee STM, Davar D, Zarour HM, Meisel M. Dietary tryptophan metabolite released by intratumoral Lactobacillus reuteri facilitates immune checkpoint inhibitor treatment. Cell. 2023;186(9):1846-1862.e26. PMCID: PMC10148916.. PubMed PMID: 37028428; PMCID: PMC10148916.
Olson DJ, Luke JJ. Myeloid Maturity: ATRA to Enhance Anti-PD-1? Clin Cancer Res. 2023-04-03;29(7):1167-1169. doi: 10.1158/1078-0432.CCR-22-3652. nihFormattedCitation: Olson DJ, Luke JJ. Myeloid Maturity: ATRA to Enhance Anti-PD-1? Clin Cancer Res. 2023;29(7):1167-1169. PMCID: PMC10073251.. PubMed PMID: 36656164; PMCID: PMC10073251.
Ruffin AT, Li H, Vujanovic L, Zandberg DP, Ferris RL, Bruno TC. Improving head and neck cancer therapies by immunomodulation of the tumour microenvironment. Nat Rev Cancer. 2023-03-01;23(3):173-188. doi: 10.1038/s41568-022-00531-9. nihFormattedCitation: Ruffin AT, Li H, Vujanovic L, Zandberg DP, Ferris RL, Bruno TC. Improving head and neck cancer therapies by immunomodulation of the tumour microenvironment. Nat Rev Cancer. 2023;23(3):173-188. PMCID: PMC9992112.. PubMed PMID: 36456755; PMCID: PMC9992112.
Karapetyan L, Luke JJ. Interferon Biology and LAG-3 Shedding in PD-(L)1 plus LAG-3 Immunotherapy. Clin Cancer Res. 2023-03-01;29(5):835-837. doi: 10.1158/1078-0432.CCR-22-3312. nihFormattedCitation: Karapetyan L, Luke JJ. Interferon Biology and LAG-3 Shedding in PD-(L)1 plus LAG-3 Immunotherapy. Clin Cancer Res. 2023;29(5):835-837. PMCID: PMC9992241.. PubMed PMID: 36534010; PMCID: PMC9992241.
Lontos K, Wang Y, Joshi SK, Frisch AT, Watson MJ, Kumar A, Menk AV, Wang Y, Cumberland R, Lohmueller J, Carrizosa E, Boyerinas B, Delgoffe GM. Metabolic reprogramming via an engineered PGC-1α improves human chimeric antigen receptor T-cell therapy against solid tumors. J Immunother Cancer. 2023-03-01;11(3): doi: 10.1136/jitc-2022-006522. nihFormattedCitation: Lontos K, Wang Y, Joshi SK, Frisch AT, Watson MJ, Kumar A, Menk AV, Wang Y, Cumberland R, Lohmueller J, Carrizosa E, Boyerinas B, Delgoffe GM. Metabolic reprogramming via an engineered PGC-1α improves human chimeric antigen receptor T-cell therapy against solid tumors. J Immunother Cancer. 2023;11(3). PMCID: PMC10016249.. PubMed PMID: 36914208; PMCID: PMC10016249.
Sacirbegovic F, Günther M, Greco A, Zhao D, Wang X, Zhou M, Rosenberger S, Oberbarnscheidt MH, Held W, McNiff J, Jain D, Höfer T, Shlomchik WD. Graft-versus-host disease is locally maintained in target tissues by resident progenitor-like T cells. Immunity. 2023-02-14;56(2):369-385.e6. doi: 10.1016/j.immuni.2023.01.003. nihFormattedCitation: Sacirbegovic F, Günther M, Greco A, Zhao D, Wang X, Zhou M, Rosenberger S, Oberbarnscheidt MH, Held W, McNiff J, Jain D, Höfer T, Shlomchik WD. Graft-versus-host disease is locally maintained in target tissues by resident progenitor-like T cells. Immunity. 2023;56(2):369-385.e6. PMCID: PMC10182785.. PubMed PMID: 36720219; PMCID: PMC10182785.
Ge H, Ferris RL, Wang JH. Cetuximab Responses in Patients with HNSCC Correlate to Clonal Expansion Feature of Peripheral and Tumor-Infiltrating T Cells with Top T-Cell Receptor Clonotypes. Clin Cancer Res. 2023-02-01;29(3):647-658. doi: 10.1158/1078-0432.CCR-22-2355. nihFormattedCitation: Ge H, Ferris RL, Wang JH. Cetuximab Responses in Patients with HNSCC Correlate to Clonal Expansion Feature of Peripheral and Tumor-Infiltrating T Cells with Top T-Cell Receptor Clonotypes. Clin Cancer Res. 2023;29(3):647-658. PMCID: PMC9898159.. PubMed PMID: 36315045; PMCID: PMC9898159.
Vignali PDA, DePeaux K, Watson MJ, Ye C, Ford BR, Lontos K, McGaa NK, Scharping NE, Menk AV, Robson SC, Poholek AC, Rivadeneira DB, Delgoffe GM. Hypoxia drives CD39-dependent suppressor function in exhausted T cells to limit antitumor immunity. Nat Immunol. 2023-02-01;24(2):267-279. doi: 10.1038/s41590-022-01379-9. nihFormattedCitation: Vignali PDA, DePeaux K, Watson MJ, Ye C, Ford BR, Lontos K, McGaa NK, Scharping NE, Menk AV, Robson SC, Poholek AC, Rivadeneira DB, Delgoffe GM. Hypoxia drives CD39-dependent suppressor function in exhausted T cells to limit antitumor immunity. Nat Immunol. 2023;24(2):267-279. PMCID: PMC10402660.. PubMed PMID: 36543958; PMCID: PMC10402660.
Augustin RC, Bao R, Luke JJ. Old Dog, New Trick: A Tumor-Intrinsic Role for PD-1 in Chemoresistant Tumor Subclones. Clin Cancer Res. 2023-02-01;29(3):505-507. doi: 10.1158/1078-0432.CCR-22-3022. nihFormattedCitation: Augustin RC, Bao R, Luke JJ. Old Dog, New Trick: A Tumor-Intrinsic Role for PD-1 in Chemoresistant Tumor Subclones. Clin Cancer Res. 2023;29(3):505-507. PMCID: PMC9898080.. PubMed PMID: 36383142; PMCID: PMC9898080.
Augustin RC, Bao R, Luke JJ. Targeting Cbl-b in cancer immunotherapy. J Immunother Cancer. 2023-02-01;11(2): doi: 10.1136/jitc-2022-006007. nihFormattedCitation: Augustin RC, Bao R, Luke JJ. Targeting Cbl-b in cancer immunotherapy. J Immunother Cancer. 2023;11(2). PMCID: PMC9906388.. PubMed PMID: 36750253; PMCID: PMC9906388.
Whiteside T, Zarour HM. In memoriam: Soldano Ferrone, MD, PhD (1940-2023). J Immunother Cancer. 2023-01-30;11(1): doi: 10.1136/jitc-2023-006761. nihFormattedCitation: Whiteside T, Zarour HM. In memoriam: Soldano Ferrone, MD, PhD (1940-2023). J Immunother Cancer. 2023;11(1). PMCID: PMC9887713.. PubMed PMID: 36717185; PMCID: PMC9887713.
Augustin RC, Luke JJ. Induction Exposure Dose of Ipilimumab and Failure of Adjuvant Nivolumab Plus Ipilimumab in Melanoma. J Clin Oncol. 2023-01-20;41(3):443-446. doi: 10.1200/JCO.22.01770. nihFormattedCitation: Augustin RC, Luke JJ. Induction Exposure Dose of Ipilimumab and Failure of Adjuvant Nivolumab Plus Ipilimumab in Melanoma. J Clin Oncol. 2023;41(3):443-446. PMCID: PMC9870232.. PubMed PMID: 36162010; PMCID: PMC9870232.
Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon Alfa-2b Adjuvant Therapy of High-Risk Resected Cutaneous Melanoma: The Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol. 2023-01-20;41(3):425-435. doi: 10.1200/JCO.22.02264. nihFormattedCitation: Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon Alfa-2b Adjuvant Therapy of High-Risk Resected Cutaneous Melanoma: The Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol. 2023;41(3):425-435.. PubMed PMID: 36649675.
Atkins MB, Lee SJ, Chmielowski B, Tarhini AA, Cohen GI, Truong TG, Moon HH, Davar D, O'Rourke M, Stephenson JJ, Curti BD, Urba WJ, Brell JM, Funchain P, Kendra KL, Ikeguchi AP, Jaslowski A, Bane CL, Taylor MA, Bajaj M, Conry RM, Ellis RJ, Logan TF, Laudi N, Sosman JA, Crockett DG, Pecora AL, Okazaki IJ, Reganti S, Chandra S, Guild S, Chen HX, Streicher HZ, Wolchok JD, Ribas A, Kirkwood JM. Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134. J Clin Oncol. 2023-01-10;41(2):186-197. doi: 10.1200/JCO.22.01763. nihFormattedCitation: Atkins MB, Lee SJ, Chmielowski B, Tarhini AA, Cohen GI, Truong TG, Moon HH, Davar D, O'Rourke M, Stephenson JJ, Curti BD, Urba WJ, Brell JM, Funchain P, Kendra KL, Ikeguchi AP, Jaslowski A, Bane CL, Taylor MA, Bajaj M, Conry RM, Ellis RJ, Logan TF, Laudi N, Sosman JA, Crockett DG, Pecora AL, Okazaki IJ, Reganti S, Chandra S, Guild S, Chen HX, Streicher HZ, Wolchok JD, Ribas A, Kirkwood JM. Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134. J Clin Oncol. 2023;41(2):186-197. PMCID: PMC9839305.. PubMed PMID: 36166727; PMCID: PMC9839305.
Zarour HM. Microbiome-derived metabolites counteract tumor-induced immunosuppression and boost immune checkpoint blockade. Cell Metab. 2022-12-06;34(12):1903-1905. doi: 10.1016/j.cmet.2022.11.010. nihFormattedCitation: Zarour HM. Microbiome-derived metabolites counteract tumor-induced immunosuppression and boost immune checkpoint blockade. Cell Metab. 2022;34(12):1903-1905.. PubMed PMID: 36476933.
Andrews LP, Cillo AR, Karapetyan L, Kirkwood JM, Workman CJ, Vignali DAA. Molecular Pathways and Mechanisms of LAG3 in Cancer Therapy. Clin Cancer Res. 2022-12-01;28(23):5030-5039. doi: 10.1158/1078-0432.CCR-21-2390. nihFormattedCitation: Andrews LP, Cillo AR, Karapetyan L, Kirkwood JM, Workman CJ, Vignali DAA. Molecular Pathways and Mechanisms of LAG3 in Cancer Therapy. Clin Cancer Res. 2022;28(23):5030-5039. PMCID: PMC9669281.. PubMed PMID: 35579997; PMCID: PMC9669281.
Anagnostou V, Luke JJ. Quantitative Spatial Profiling of TILs as the Next Step beyond PD-L1 Testing for Immune Checkpoint Blockade. Clin Cancer Res. 2022-11-14;28(22):4835-4837. doi: 10.1158/1078-0432.CCR-22-2277. nihFormattedCitation: Anagnostou V, Luke JJ. Quantitative Spatial Profiling of TILs as the Next Step beyond PD-L1 Testing for Immune Checkpoint Blockade. Clin Cancer Res. 2022;28(22):4835-4837. PMCID: PMC9669208.. PubMed PMID: 36103258; PMCID: PMC9669208.
Puthanmadhom Narayanan S, Najjar YG. Hereditary Cancer Syndromes-A Broader Clinical Spectrum Than Previously Understood? JAMA Oncol. 2022-11-01;8(11):1698-1699. doi: 10.1001/jamaoncol.2022.3776. nihFormattedCitation: Puthanmadhom Narayanan S, Najjar YG. Hereditary Cancer Syndromes-A Broader Clinical Spectrum Than Previously Understood? JAMA Oncol. 2022;8(11):1698-1699.. PubMed PMID: 36048458.
Sun R, Gao DS, Shoush J, Lu B. The IL-1 family in tumorigenesis and antitumor immunity. Semin Cancer Biol. 2022-11-01;86(Pt 2):280-295. doi: 10.1016/j.semcancer.2022.05.002. nihFormattedCitation: Sun R, Gao DS, Shoush J, Lu B. The IL-1 family in tumorigenesis and antitumor immunity. Semin Cancer Biol. 2022;86(Pt 2):280-295.. PubMed PMID: 35580824.
Davar D, Zarour HM. Facts and Hopes for Gut Microbiota Interventions in Cancer Immunotherapy. Clin Cancer Res. 2022-10-14;28(20):4370-4384. doi: 10.1158/1078-0432.CCR-21-1129. nihFormattedCitation: Davar D, Zarour HM. Facts and Hopes for Gut Microbiota Interventions in Cancer Immunotherapy. Clin Cancer Res. 2022;28(20):4370-4384. PMCID: PMC9561605.. PubMed PMID: 35748749; PMCID: PMC9561605.
Hassel JC, Luke JJ. Autoantibodies as Predictors for Clinical Outcome and Toxicity for Immunotherapy. Clin Cancer Res. 2022-09-15;28(18):3914-3916. doi: 10.1158/1078-0432.CCR-22-1664. nihFormattedCitation: Hassel JC, Luke JJ. Autoantibodies as Predictors for Clinical Outcome and Toxicity for Immunotherapy. Clin Cancer Res. 2022;28(18):3914-3916. PMCID: PMC9494631.. PubMed PMID: 36106401; PMCID: PMC9494631.
Davar D, Zappasodi R, Wang H, Naik GS, Sato T, Bauer T, Bajor D, Rixe O, Newman W, Qi J, Holland A, Wong P, Sifferlen L, Piper D, Sirard CA, Merghoub T, Wolchok JD, Luke JJ. Phase IB Study of GITR Agonist Antibody TRX518 Singly and in Combination with Gemcitabine, Pembrolizumab, or Nivolumab in Patients with Advanced Solid Tumors. Clin Cancer Res. 2022-09-15;28(18):3990-4002. doi: 10.1158/1078-0432.CCR-22-0339. nihFormattedCitation: Davar D, Zappasodi R, Wang H, Naik GS, Sato T, Bauer T, Bajor D, Rixe O, Newman W, Qi J, Holland A, Wong P, Sifferlen L, Piper D, Sirard CA, Merghoub T, Wolchok JD, Luke JJ. Phase IB Study of GITR Agonist Antibody TRX518 Singly and in Combination with Gemcitabine, Pembrolizumab, or Nivolumab in Patients with Advanced Solid Tumors. Clin Cancer Res. 2022;28(18):3990-4002. PMCID: PMC9475244.. PubMed PMID: 35499569; PMCID: PMC9475244.
Luke JJ, Ibrahim N, Eggermont AM. Adjuvant therapy in stage IIB and IIC melanoma: is sentinel biopsy needed? - Authors' reply. Lancet. 2022-08-20;400(10352):559-560. doi: 10.1016/S0140-6736(22)01350-2. nihFormattedCitation: Luke JJ, Ibrahim N, Eggermont AM. Adjuvant therapy in stage IIB and IIC melanoma: is sentinel biopsy needed? - Authors' reply. Lancet. 2022;400(10352):559-560.. PubMed PMID: 35988561.
Tarhini AA, Eads JR, Moore KN, Tatard-Leitman V, Wright J, Forde PM, Ferris RL. Neoadjuvant immunotherapy of locoregionally advanced solid tumors. J Immunother Cancer. 2022-08-01;10(8): doi: 10.1136/jitc-2022-005036. nihFormattedCitation: Tarhini AA, Eads JR, Moore KN, Tatard-Leitman V, Wright J, Forde PM, Ferris RL. Neoadjuvant immunotherapy of locoregionally advanced solid tumors. J Immunother Cancer. 2022;10(8). PMCID: PMC9386211.. PubMed PMID: 35973745; PMCID: PMC9386211.
Eggermont AMM, Hamid O, Long GV, Luke JJ. Optimal systemic therapy for high-risk resectable melanoma. Nat Rev Clin Oncol. 2022-07-01;19(7):431-439. doi: 10.1038/s41571-022-00630-4. nihFormattedCitation: Eggermont AMM, Hamid O, Long GV, Luke JJ. Optimal systemic therapy for high-risk resectable melanoma. Nat Rev Clin Oncol. 2022;19(7):431-439. PMCID: PMC11075933.. PubMed PMID: 35468949; PMCID: PMC11075933.
Filderman JN, Storkus WJ. Finding the right help in the tumor microenvironment. J Clin Invest. 2022-06-15;132(12): doi: 10.1172/JCI161052. nihFormattedCitation: Filderman JN, Storkus WJ. Finding the right help in the tumor microenvironment. J Clin Invest. 2022;132(12). PMCID: PMC9197508.. PubMed PMID: 35703176; PMCID: PMC9197508.
Grebinoski S, Zhang Q, Cillo AR, Manne S, Xiao H, Brunazzi EA, Tabib T, Cardello C, Lian CG, Murphy GF, Lafyatis R, Wherry EJ, Das J, Workman CJ, Vignali DAA. Autoreactive CD8(+) T cells are restrained by an exhaustion-like program that is maintained by LAG3. Nat Immunol. 2022-06-01;23(6):868-877. doi: 10.1038/s41590-022-01210-5. nihFormattedCitation: Grebinoski S, Zhang Q, Cillo AR, Manne S, Xiao H, Brunazzi EA, Tabib T, Cardello C, Lian CG, Murphy GF, Lafyatis R, Wherry EJ, Das J, Workman CJ, Vignali DAA. Autoreactive CD8(+) T cells are restrained by an exhaustion-like program that is maintained by LAG3. Nat Immunol. 2022;23(6):868-877. PMCID: PMC9179227.. PubMed PMID: 35618829; PMCID: PMC9179227.
Orr B, Mahdi H, Fang Y, Strange M, Uygun I, Rana M, Zhang L, Suarez Mora A, Pusateri A, Elishaev E, Kang C, Tseng G, Gooding W, Edwards RP, Kalinski P, Vlad AM. Phase I Trial Combining Chemokine-Targeting with Loco-Regional Chemoimmunotherapy for Recurrent, Platinum-Sensitive Ovarian Cancer Shows Induction of CXCR3 Ligands and Markers of Type 1 Immunity. Clin Cancer Res. 2022-05-13;28(10):2038-2049. doi: 10.1158/1078-0432.CCR-21-3659. nihFormattedCitation: Orr B, Mahdi H, Fang Y, Strange M, Uygun I, Rana M, Zhang L, Suarez Mora A, Pusateri A, Elishaev E, Kang C, Tseng G, Gooding W, Edwards RP, Kalinski P, Vlad AM. Phase I Trial Combining Chemokine-Targeting with Loco-Regional Chemoimmunotherapy for Recurrent, Platinum-Sensitive Ovarian Cancer Shows Induction of CXCR3 Ligands and Markers of Type 1 Immunity. Clin Cancer Res. 2022;28(10):2038-2049. PMCID: PMC9106847.. PubMed PMID: 35046055; PMCID: PMC9106847.
Shurin MR, Umansky V. Cross-talk between HIF and PD-1/PD-L1 pathways in carcinogenesis and therapy. J Clin Invest. 2022-05-02;132(9): doi: 10.1172/JCI159473. nihFormattedCitation: Shurin MR, Umansky V. Cross-talk between HIF and PD-1/PD-L1 pathways in carcinogenesis and therapy. J Clin Invest. 2022;132(9). PMCID: PMC9057611.. PubMed PMID: 35499071; PMCID: PMC9057611.
Pagliano O, Morrison RM, Chauvin JM, Banerjee H, Davar D, Ding Q, Tanegashima T, Gao W, Chakka SR, DeBlasio R, Lowin A, Kara K, Ka M, Zidi B, Amin R, Raphael I, Zhang S, Watkins SC, Sander C, Kirkwood JM, Bosenberg M, Anderson AC, Kuchroo VK, Kane LP, Korman AJ, Rajpal A, West SM, Han M, Bee C, Deng X, Schebye XM, Strop P, Zarour HM. Tim-3 mediates T cell trogocytosis to limit antitumor immunity. J Clin Invest. 2022-05-02;132(9): doi: 10.1172/JCI152864. nihFormattedCitation: Pagliano O, Morrison RM, Chauvin JM, Banerjee H, Davar D, Ding Q, Tanegashima T, Gao W, Chakka SR, DeBlasio R, Lowin A, Kara K, Ka M, Zidi B, Amin R, Raphael I, Zhang S, Watkins SC, Sander C, Kirkwood JM, Bosenberg M, Anderson AC, Kuchroo VK, Kane LP, Korman AJ, Rajpal A, West SM, Han M, Bee C, Deng X, Schebye XM, Strop P, Zarour HM. Tim-3 mediates T cell trogocytosis to limit antitumor immunity. J Clin Invest. 2022;132(9). PMCID: PMC9057587.. PubMed PMID: 35316223; PMCID: PMC9057587.
Nayak DA, Binder RJ. Agents of cancer immunosurveillance: HSPs and dsDNA. Trends Immunol. 2022-05-01;43(5):404-413. doi: 10.1016/j.it.2022.03.004. nihFormattedCitation: Nayak DA, Binder RJ. Agents of cancer immunosurveillance: HSPs and dsDNA. Trends Immunol. 2022;43(5):404-413. PMCID: PMC9058224.. PubMed PMID: 35382994; PMCID: PMC9058224.
Guy C, Mitrea DM, Chou PC, Temirov J, Vignali KM, Liu X, Zhang H, Kriwacki R, Bruchez MP, Watkins SC, Workman CJ, Vignali DAA. LAG3 associates with TCR-CD3 complexes and suppresses signaling by driving co-receptor-Lck dissociation. Nat Immunol. 2022-05-01;23(5):757-767. doi: 10.1038/s41590-022-01176-4. nihFormattedCitation: Guy C, Mitrea DM, Chou PC, Temirov J, Vignali KM, Liu X, Zhang H, Kriwacki R, Bruchez MP, Watkins SC, Workman CJ, Vignali DAA. LAG3 associates with TCR-CD3 complexes and suppresses signaling by driving co-receptor-Lck dissociation. Nat Immunol. 2022;23(5):757-767. PMCID: PMC9106921.. PubMed PMID: 35437325; PMCID: PMC9106921.
Luke JJ, Rutkowski P, Queirolo P, Del Vecchio M, Mackiewicz J, Chiarion-Sileni V, de la Cruz Merino L, Khattak MA, Schadendorf D, Long GV, Ascierto PA, Mandala M, De Galitiis F, Haydon A, Dummer R, Grob JJ, Robert C, Carlino MS, Mohr P, Poklepovic A, Sondak VK, Scolyer RA, Kirkwood JM, Chen K, Diede SJ, Ahsan S, Ibrahim N, Eggermont AMM, KEYNOTE-716 Investigators. Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial. Lancet. 2022-04-30;399(10336):1718-1729. doi: 10.1016/S0140-6736(22)00562-1. nihFormattedCitation: Luke JJ, Rutkowski P, Queirolo P, Del Vecchio M, Mackiewicz J, Chiarion-Sileni V, de la Cruz Merino L, Khattak MA, Schadendorf D, Long GV, Ascierto PA, Mandala M, De Galitiis F, Haydon A, Dummer R, Grob JJ, Robert C, Carlino MS, Mohr P, Poklepovic A, Sondak VK, Scolyer RA, Kirkwood JM, Chen K, Diede SJ, Ahsan S, Ibrahim N, Eggermont AMM, KEYNOTE-716 Investigators. Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial. Lancet. 2022;399(10336):1718-1729.. PubMed PMID: 35367007.
Bleakley M, Sehgal A, Seropian S, Biernacki MA, Krakow EF, Dahlberg A, Persinger H, Hilzinger B, Martin PJ, Carpenter PA, Flowers ME, Voutsinas J, Gooley TA, Loeb K, Wood BL, Heimfeld S, Riddell SR, Shlomchik WD. Naive T-Cell Depletion to Prevent Chronic Graft-Versus-Host Disease. J Clin Oncol. 2022-04-10;40(11):1174-1185. doi: 10.1200/JCO.21.01755. nihFormattedCitation: Bleakley M, Sehgal A, Seropian S, Biernacki MA, Krakow EF, Dahlberg A, Persinger H, Hilzinger B, Martin PJ, Carpenter PA, Flowers ME, Voutsinas J, Gooley TA, Loeb K, Wood BL, Heimfeld S, Riddell SR, Shlomchik WD. Naive T-Cell Depletion to Prevent Chronic Graft-Versus-Host Disease. J Clin Oncol. 2022;40(11):1174-1185. PMCID: PMC8987226.. PubMed PMID: 35007144; PMCID: PMC8987226.
Ferris RL, Moskovitz J, Kunning S, Ruffin AT, Reeder C, Ohr J, Gooding WE, Kim S, Karlovits BJ, Vignali DAA, Duvvuri U, Johnson JT, Petro D, Heron DE, Clump DA, Bruno TC, Bauman JE. Phase I Trial of Cetuximab, Radiotherapy, and Ipilimumab in Locally Advanced Head and Neck Cancer. Clin Cancer Res. 2022-04-01;28(7):1335-1344. doi: 10.1158/1078-0432.CCR-21-0426. nihFormattedCitation: Ferris RL, Moskovitz J, Kunning S, Ruffin AT, Reeder C, Ohr J, Gooding WE, Kim S, Karlovits BJ, Vignali DAA, Duvvuri U, Johnson JT, Petro D, Heron DE, Clump DA, Bruno TC, Bauman JE. Phase I Trial of Cetuximab, Radiotherapy, and Ipilimumab in Locally Advanced Head and Neck Cancer. Clin Cancer Res. 2022;28(7):1335-1344. PMCID: PMC9164766.. PubMed PMID: 35091445; PMCID: PMC9164766.
Ferris RL, Burtness B, Flamand Y. Reply to A.S. Garden. J Clin Oncol. 2022-04-01;40(10):1133-1134. doi: 10.1200/JCO.22.00063. nihFormattedCitation: Ferris RL, Burtness B, Flamand Y. Reply to A.S. Garden. J Clin Oncol. 2022;40(10):1133-1134.. PubMed PMID: 35171688.
Gocher AM, Workman CJ, Vignali DAA. Interferon-γ: teammate or opponent in the tumour microenvironment? Nat Rev Immunol. 2022-03-01;22(3):158-172. doi: 10.1038/s41577-021-00566-3. nihFormattedCitation: Gocher AM, Workman CJ, Vignali DAA. Interferon-γ: teammate or opponent in the tumour microenvironment? Nat Rev Immunol. 2022;22(3):158-172. PMCID: PMC8688586.. PubMed PMID: 34155388; PMCID: PMC8688586.
Meric-Bernstam F, Sweis RF, Hodi FS, Messersmith WA, Andtbacka RHI, Ingham M, Lewis N, Chen X, Pelletier M, Chen X, Wu J, McWhirter SM, Müller T, Nair N, Luke JJ. Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas. Clin Cancer Res. 2022-02-15;28(4):677-688. doi: 10.1158/1078-0432.CCR-21-1963. nihFormattedCitation: Meric-Bernstam F, Sweis RF, Hodi FS, Messersmith WA, Andtbacka RHI, Ingham M, Lewis N, Chen X, Pelletier M, Chen X, Wu J, McWhirter SM, Müller T, Nair N, Luke JJ. Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas. Clin Cancer Res. 2022;28(4):677-688.. PubMed PMID: 34716197.
Augustin RC, Leone RD, Naing A, Fong L, Bao R, Luke JJ. Next steps for clinical translation of adenosine pathway inhibition in cancer immunotherapy. J Immunother Cancer. 2022-02-01;10(2): doi: 10.1136/jitc-2021-004089. nihFormattedCitation: Augustin RC, Leone RD, Naing A, Fong L, Bao R, Luke JJ. Next steps for clinical translation of adenosine pathway inhibition in cancer immunotherapy. J Immunother Cancer. 2022;10(2). PMCID: PMC8830302.. PubMed PMID: 35135866; PMCID: PMC8830302.
Wang W, Prokopec JS, Zhang Y, Sukhoplyasova M, Shinglot H, Wang MT, Linkermann A, Stewart-Ornstein J, Gong YN. Sensing plasma membrane pore formation induces chemokine production in survivors of regulated necrosis. Dev Cell. 2022-01-24;57(2):228-245.e6. doi: 10.1016/j.devcel.2021.12.015. nihFormattedCitation: Wang W, Prokopec JS, Zhang Y, Sukhoplyasova M, Shinglot H, Wang MT, Linkermann A, Stewart-Ornstein J, Gong YN. Sensing plasma membrane pore formation induces chemokine production in survivors of regulated necrosis. Dev Cell. 2022;57(2):228-245.e6. PMCID: PMC8792343.. PubMed PMID: 35016014; PMCID: PMC8792343.
Watson MJ, Delgoffe GM. Fighting in a wasteland: deleterious metabolites and antitumor immunity. J Clin Invest. 2022-01-18;132(2): doi: 10.1172/JCI148549. nihFormattedCitation: Watson MJ, Delgoffe GM. Fighting in a wasteland: deleterious metabolites and antitumor immunity. J Clin Invest. 2022;132(2). PMCID: PMC8759785.. PubMed PMID: 35040434; PMCID: PMC8759785.
Ferris RL, Flamand Y, Weinstein GS, Li S, Quon H, Mehra R, Garcia JJ, Chung CH, Gillison ML, Duvvuri U, O'Malley BW Jr, Ozer E, Thomas GR, Koch WM, Gross ND, Bell RB, Saba NF, Lango M, Méndez E, Burtness B. Phase II Randomized Trial of Transoral Surgery and Low-Dose Intensity Modulated Radiation Therapy in Resectable p16+ Locally Advanced Oropharynx Cancer: An ECOG-ACRIN Cancer Research Group Trial (E3311). J Clin Oncol. 2022-01-10;40(2):138-149. doi: 10.1200/JCO.21.01752. nihFormattedCitation: Ferris RL, Flamand Y, Weinstein GS, Li S, Quon H, Mehra R, Garcia JJ, Chung CH, Gillison ML, Duvvuri U, O'Malley BW Jr, Ozer E, Thomas GR, Koch WM, Gross ND, Bell RB, Saba NF, Lango M, Méndez E, Burtness B. Phase II Randomized Trial of Transoral Surgery and Low-Dose Intensity Modulated Radiation Therapy in Resectable p16+ Locally Advanced Oropharynx Cancer: An ECOG-ACRIN Cancer Research Group Trial (E3311). J Clin Oncol. 2022;40(2):138-149. PMCID: PMC8718241.. PubMed PMID: 34699271; PMCID: PMC8718241.
Tarhini AA, Lee SJ, Tan AC, El Naqa IM, Stephen Hodi F, Butterfield LH, LaFramboise WA, Storkus WJ, Karunamurthy AD, Conejo-Garcia JR, Hwu P, Streicher H, Sondak VK, Kirkwood JM. Improved prognosis and evidence of enhanced immunogenicity in tumor and circulation of high-risk melanoma patients with unknown primary. J Immunother Cancer. 2022-01-01;10(1): doi: 10.1136/jitc-2021-004310. nihFormattedCitation: Tarhini AA, Lee SJ, Tan AC, El Naqa IM, Stephen Hodi F, Butterfield LH, LaFramboise WA, Storkus WJ, Karunamurthy AD, Conejo-Garcia JR, Hwu P, Streicher H, Sondak VK, Kirkwood JM. Improved prognosis and evidence of enhanced immunogenicity in tumor and circulation of high-risk melanoma patients with unknown primary. J Immunother Cancer. 2022;10(1). PMCID: PMC8788316.. PubMed PMID: 35074904; PMCID: PMC8788316.
Weisel NM, Joachim SM, Smita S, Callahan D, Elsner RA, Conter LJ, Chikina M, Farber DL, Weisel FJ, Shlomchik MJ. Surface phenotypes of naive and memory B cells in mouse and human tissues. Nat Immunol. 2022-01-01;23(1):135-145. doi: 10.1038/s41590-021-01078-x. nihFormattedCitation: Weisel NM, Joachim SM, Smita S, Callahan D, Elsner RA, Conter LJ, Chikina M, Farber DL, Weisel FJ, Shlomchik MJ. Surface phenotypes of naive and memory B cells in mouse and human tissues. Nat Immunol. 2022;23(1):135-145. PMCID: PMC8712407.. PubMed PMID: 34937918; PMCID: PMC8712407.
Kürten CHL, Kulkarni A, Cillo AR, Santos PM, Roble AK, Onkar S, Reeder C, Lang S, Chen X, Duvvuri U, Kim S, Liu A, Tabib T, Lafyatis R, Feng J, Gao SJ, Bruno TC, Vignali DAA, Lu X, Bao R, Vujanovic L, Ferris RL. Investigating immune and non-immune cell interactions in head and neck tumors by single-cell RNA sequencing. Nat Commun. 2021-12-17;12(1):7338. doi: 10.1038/s41467-021-27619-4. nihFormattedCitation: Kürten CHL, Kulkarni A, Cillo AR, Santos PM, Roble AK, Onkar S, Reeder C, Lang S, Chen X, Duvvuri U, Kim S, Liu A, Tabib T, Lafyatis R, Feng J, Gao SJ, Bruno TC, Vignali DAA, Lu X, Bao R, Vujanovic L, Ferris RL. Investigating immune and non-immune cell interactions in head and neck tumors by single-cell RNA sequencing. Nat Commun. 2021;12(1):7338. PMCID: PMC8683505.. PubMed PMID: 34921143; PMCID: PMC8683505.
Overacre-Delgoffe AE, Bumgarner HJ, Cillo AR, Burr AHP, Tometich JT, Bhattacharjee A, Bruno TC, Vignali DAA, Hand TW. Microbiota-specific T follicular helper cells drive tertiary lymphoid structures and anti-tumor immunity against colorectal cancer. Immunity. 2021-12-14;54(12):2812-2824.e4. doi: 10.1016/j.immuni.2021.11.003. nihFormattedCitation: Overacre-Delgoffe AE, Bumgarner HJ, Cillo AR, Burr AHP, Tometich JT, Bhattacharjee A, Bruno TC, Vignali DAA, Hand TW. Microbiota-specific T follicular helper cells drive tertiary lymphoid structures and anti-tumor immunity against colorectal cancer. Immunity. 2021;54(12):2812-2824.e4. PMCID: PMC8865366.. PubMed PMID: 34861182; PMCID: PMC8865366.
Chuckran CA, Cillo AR, Moskovitz J, Overacre-Delgoffe A, Somasundaram AS, Shan F, Magnon GC, Kunning SR, Abecassis I, Zureikat AH, Luketich J, Pennathur A, Sembrat J, Rojas M, Merrick DT, Taylor SE, Orr B, Modugno F, Buckanovich R, Schoen RE, Kim S, Duvvuri U, Zeh H, Edwards R, Kirkwood JM, Coffman L, Ferris RL, Bruno TC, Vignali DAA. Prevalence of intratumoral regulatory T cells expressing neuropilin-1 is associated with poorer outcomes in patients with cancer. Sci Transl Med. 2021-12-08;13(623):eabf8495. doi: 10.1126/scitranslmed.abf8495. nihFormattedCitation: Chuckran CA, Cillo AR, Moskovitz J, Overacre-Delgoffe A, Somasundaram AS, Shan F, Magnon GC, Kunning SR, Abecassis I, Zureikat AH, Luketich J, Pennathur A, Sembrat J, Rojas M, Merrick DT, Taylor SE, Orr B, Modugno F, Buckanovich R, Schoen RE, Kim S, Duvvuri U, Zeh H, Edwards R, Kirkwood JM, Coffman L, Ferris RL, Bruno TC, Vignali DAA. Prevalence of intratumoral regulatory T cells expressing neuropilin-1 is associated with poorer outcomes in patients with cancer. Sci Transl Med. 2021;13(623):eabf8495. PMCID: PMC9022491.. PubMed PMID: 34878821; PMCID: PMC9022491.
DePeaux K, Delgoffe GM. Metabolic barriers to cancer immunotherapy. Nat Rev Immunol. 2021-12-01;21(12):785-797. doi: 10.1038/s41577-021-00541-y. nihFormattedCitation: DePeaux K, Delgoffe GM. Metabolic barriers to cancer immunotherapy. Nat Rev Immunol. 2021;21(12):785-797. PMCID: PMC8553800.. PubMed PMID: 33927375; PMCID: PMC8553800.
Storkus WJ, Maurer D, Lin Y, Ding F, Bose A, Lowe D, Rose A, DeMark M, Karapetyan L, Taylor JL, Chelvanambi M, Fecek RJ, Filderman JN, Looney TJ, Miller L, Linch E, Lowman GM, Kalinski P, Butterfield LH, Tarhini A, Tawbi H, Kirkwood JM. Dendritic cell vaccines targeting tumor blood vessel antigens in combination with dasatinib induce therapeutic immune responses in patients with checkpoint-refractory advanced melanoma. J Immunother Cancer. 2021-11-01;9(11): doi: 10.1136/jitc-2021-003675. nihFormattedCitation: Storkus WJ, Maurer D, Lin Y, Ding F, Bose A, Lowe D, Rose A, DeMark M, Karapetyan L, Taylor JL, Chelvanambi M, Fecek RJ, Filderman JN, Looney TJ, Miller L, Linch E, Lowman GM, Kalinski P, Butterfield LH, Tarhini A, Tawbi H, Kirkwood JM. Dendritic cell vaccines targeting tumor blood vessel antigens in combination with dasatinib induce therapeutic immune responses in patients with checkpoint-refractory advanced melanoma. J Immunother Cancer. 2021;9(11). PMCID: PMC8593702.. PubMed PMID: 34782430; PMCID: PMC8593702.
Vats K, Kruglov O, Mizes A, Samovich SN, Amoscato AA, Tyurin VA, Tyurina YY, Kagan VE, Bunimovich YL. Keratinocyte death by ferroptosis initiates skin inflammation after UVB exposure. Redox Biol. 2021-11-01;47102143. doi: 10.1016/j.redox.2021.102143. nihFormattedCitation: Vats K, Kruglov O, Mizes A, Samovich SN, Amoscato AA, Tyurin VA, Tyurina YY, Kagan VE, Bunimovich YL. Keratinocyte death by ferroptosis initiates skin inflammation after UVB exposure. Redox Biol. 2021;47:102143. PMCID: PMC8487085.. PubMed PMID: 34592565; PMCID: PMC8487085.
Foster CC, Fleming GF, Karrison TG, Liao CY, Desai AV, Moroney JW, Ratain MJ, Nanda R, Polite BN, Hahn OM, O'Donnell PH, Vokes EE, Kindler HL, Hseu R, Janisch LA, Dai J, Hoffman MD, Weichselbaum RR, Pitroda SP, Chmura SJ, Luke JJ. Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid Tumors. Clin Cancer Res. 2021-10-15;27(20):5510-5518. doi: 10.1158/1078-0432.CCR-21-0810. nihFormattedCitation: Foster CC, Fleming GF, Karrison TG, Liao CY, Desai AV, Moroney JW, Ratain MJ, Nanda R, Polite BN, Hahn OM, O'Donnell PH, Vokes EE, Kindler HL, Hseu R, Janisch LA, Dai J, Hoffman MD, Weichselbaum RR, Pitroda SP, Chmura SJ, Luke JJ. Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid Tumors. Clin Cancer Res. 2021;27(20):5510-5518.. PubMed PMID: 34168049.
Andrews LP, Vignali KM, Szymczak-Workman AL, Burton AR, Brunazzi EA, Ngiow SF, Harusato A, Sharpe AH, Wherry EJ, Taniuchi I, Workman CJ, Vignali DAA. A Cre-driven allele-conditioning line to interrogate CD4(+) conventional T cells. Immunity. 2021-10-12;54(10):2209-2217.e6. doi: 10.1016/j.immuni.2021.08.029. nihFormattedCitation: Andrews LP, Vignali KM, Szymczak-Workman AL, Burton AR, Brunazzi EA, Ngiow SF, Harusato A, Sharpe AH, Wherry EJ, Taniuchi I, Workman CJ, Vignali DAA. A Cre-driven allele-conditioning line to interrogate CD4(+) conventional T cells. Immunity. 2021;54(10):2209-2217.e6.. PubMed PMID: 34551314.
Jameson-Lee M, Luke JJ. Ipilimumab Combination Dosing: Less is More. Clin Cancer Res. 2021-10-01;27(19):5153-5155. doi: 10.1158/1078-0432.CCR-21-2406. nihFormattedCitation: Jameson-Lee M, Luke JJ. Ipilimumab Combination Dosing: Less is More. Clin Cancer Res. 2021;27(19):5153-5155. PMCID: PMC8807780.. PubMed PMID: 34341015; PMCID: PMC8807780.
Yang X, Karapetyan L, Kirkwood JM. Safety and Efficacy of Checkpoint Inhibition in Patients With Melanoma and Preexisting Autoimmune Disease. Ann Intern Med. 2021-09-01;174(9):1345. doi: 10.7326/L21-0441. nihFormattedCitation: Yang X, Karapetyan L, Kirkwood JM. Safety and Efficacy of Checkpoint Inhibition in Patients With Melanoma and Preexisting Autoimmune Disease. Ann Intern Med. 2021;174(9):1345.. PubMed PMID: 34543597.
Olson DJ, Eroglu Z, Brockstein B, Poklepovic AS, Bajaj M, Babu S, Hallmeyer S, Velasco M, Lutzky J, Higgs E, Bao R, Carll TC, Labadie B, Krausz T, Zha Y, Karrison T, Sondak VK, Gajewski TF, Khushalani NI, Luke JJ. Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma. J Clin Oncol. 2021-08-20;39(24):2647-2655. doi: 10.1200/JCO.21.00079. nihFormattedCitation: Olson DJ, Eroglu Z, Brockstein B, Poklepovic AS, Bajaj M, Babu S, Hallmeyer S, Velasco M, Lutzky J, Higgs E, Bao R, Carll TC, Labadie B, Krausz T, Zha Y, Karrison T, Sondak VK, Gajewski TF, Khushalani NI, Luke JJ. Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma. J Clin Oncol. 2021;39(24):2647-2655. PMCID: PMC8376314.. PubMed PMID: 33945288; PMCID: PMC8376314.
Najjar YG, McCurry D, Lin H, Lin Y, Zang Y, Davar D, Karunamurthy A, Drabick JJ, Neves RI, Butterfield LH, Ernstoff MS, Puzanov I, Skitzki JJ, Bordeaux J, Summit IB, Bender JO, Kim JY, Chen B, Sarikonda G, Pahuja A, Tsau J, Alfonso Z, Laing C, Pingpank JF, Holtzman MP, Sander C, Rose A, Zarour HM, Kirkwood JM, Tarhini AA. Neoadjuvant Pembrolizumab and High-Dose IFNα-2b in Resectable Regionally Advanced Melanoma. Clin Cancer Res. 2021-08-01;27(15):4195-4204. doi: 10.1158/1078-0432.CCR-20-4301. nihFormattedCitation: Najjar YG, McCurry D, Lin H, Lin Y, Zang Y, Davar D, Karunamurthy A, Drabick JJ, Neves RI, Butterfield LH, Ernstoff MS, Puzanov I, Skitzki JJ, Bordeaux J, Summit IB, Bender JO, Kim JY, Chen B, Sarikonda G, Pahuja A, Tsau J, Alfonso Z, Laing C, Pingpank JF, Holtzman MP, Sander C, Rose A, Zarour HM, Kirkwood JM, Tarhini AA. Neoadjuvant Pembrolizumab and High-Dose IFNα-2b in Resectable Regionally Advanced Melanoma. Clin Cancer Res. 2021;27(15):4195-4204. PMCID: PMC8338751.. PubMed PMID: 33753453; PMCID: PMC8338751.
Emens LA, Adams S, Cimino-Mathews A, Disis ML, Gatti-Mays ME, Ho AY, Kalinsky K, McArthur HL, Mittendorf EA, Nanda R, Page DB, Rugo HS, Rubin KM, Soliman H, Spears PA, Tolaney SM, Litton JK. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer. J Immunother Cancer. 2021-08-01;9(8): doi: 10.1136/jitc-2021-002597. nihFormattedCitation: Emens LA, Adams S, Cimino-Mathews A, Disis ML, Gatti-Mays ME, Ho AY, Kalinsky K, McArthur HL, Mittendorf EA, Nanda R, Page DB, Rugo HS, Rubin KM, Soliman H, Spears PA, Tolaney SM, Litton JK. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer. J Immunother Cancer. 2021;9(8). PMCID: PMC8365813.. PubMed PMID: 34389617; PMCID: PMC8365813.
Brown CC, Gottschalk RA. Volume control: Turning the dial on regulatory T cells. Cell. 2021-07-22;184(15):3847-3849. doi: 10.1016/j.cell.2021.06.015. nihFormattedCitation: Brown CC, Gottschalk RA. Volume control: Turning the dial on regulatory T cells. Cell. 2021;184(15):3847-3849.. PubMed PMID: 34297928.
Patel RB, Hernandez R, Carlson P, Grudzinski J, Bates AM, Jagodinsky JC, Erbe A, Marsh IR, Arthur I, Aluicio-Sarduy E, Sriramaneni RN, Jin WJ, Massey C, Rakhmilevich AL, Vail D, Engle JW, Le T, Kim K, Bednarz B, Sondel PM, Weichert J, Morris ZS. Low-dose targeted radionuclide therapy renders immunologically cold tumors responsive to immune checkpoint blockade. Sci Transl Med. 2021-07-14;13(602): doi: 10.1126/scitranslmed.abb3631. nihFormattedCitation: Patel RB, Hernandez R, Carlson P, Grudzinski J, Bates AM, Jagodinsky JC, Erbe A, Marsh IR, Arthur I, Aluicio-Sarduy E, Sriramaneni RN, Jin WJ, Massey C, Rakhmilevich AL, Vail D, Engle JW, Le T, Kim K, Bednarz B, Sondel PM, Weichert J, Morris ZS. Low-dose targeted radionuclide therapy renders immunologically cold tumors responsive to immune checkpoint blockade. Sci Transl Med. 2021;13(602). PMCID: PMC8449934.. PubMed PMID: 34261797; PMCID: PMC8449934.
Najjar YG. Search for effective treatments in patients with advanced refractory melanoma continues: can novel intratumoral therapies deliver? J Immunother Cancer. 2021-07-01;9(7): doi: 10.1136/jitc-2021-002820. nihFormattedCitation: Najjar YG. Search for effective treatments in patients with advanced refractory melanoma continues: can novel intratumoral therapies deliver? J Immunother Cancer. 2021;9(7). PMCID: PMC8314703.. PubMed PMID: 34312244; PMCID: PMC8314703.
Ruffin AT, Cillo AR, Tabib T, Liu A, Onkar S, Kunning SR, Lampenfeld C, Atiya HI, Abecassis I, Kürten CHL, Qi Z, Soose R, Duvvuri U, Kim S, Oesterrich S, Lafyatis R, Coffman LG, Ferris RL, Vignali DAA, Bruno TC. B cell signatures and tertiary lymphoid structures contribute to outcome in head and neck squamous cell carcinoma. Nat Commun. 2021-06-07;12(1):3349. doi: 10.1038/s41467-021-23355-x. nihFormattedCitation: Ruffin AT, Cillo AR, Tabib T, Liu A, Onkar S, Kunning SR, Lampenfeld C, Atiya HI, Abecassis I, Kürten CHL, Qi Z, Soose R, Duvvuri U, Kim S, Oesterrich S, Lafyatis R, Coffman LG, Ferris RL, Vignali DAA, Bruno TC. B cell signatures and tertiary lymphoid structures contribute to outcome in head and neck squamous cell carcinoma. Nat Commun. 2021;12(1):3349. PMCID: PMC8184766.. PubMed PMID: 34099645; PMCID: PMC8184766.
Ferris RL, Spanos WC, Leidner R, Gonçalves A, Martens UM, Kyi C, Sharfman W, Chung CH, Devriese LA, Gauthier H, Chiosea SI, Vujanovic L, Taube JM, Stein JE, Li J, Li B, Chen T, Barrows A, Topalian SL. Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial. J Immunother Cancer. 2021-06-01;9(6): doi: 10.1136/jitc-2021-002568. nihFormattedCitation: Ferris RL, Spanos WC, Leidner R, Gonçalves A, Martens UM, Kyi C, Sharfman W, Chung CH, Devriese LA, Gauthier H, Chiosea SI, Vujanovic L, Taube JM, Stein JE, Li J, Li B, Chen T, Barrows A, Topalian SL. Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial. J Immunother Cancer. 2021;9(6). PMCID: PMC8183204.. PubMed PMID: 34083421; PMCID: PMC8183204.
Cheemalavagu N, Gottschalk RA. Time will tell: The temporal code of immune threats. Immunity. 2021-05-11;54(5):845-847. doi: 10.1016/j.immuni.2021.04.018. nihFormattedCitation: Cheemalavagu N, Gottschalk RA. Time will tell: The temporal code of immune threats. Immunity. 2021;54(5):845-847.. PubMed PMID: 33979580.
Lai SY, Ferris RL. Reply to N. Hirshoren et al and D. Chakrabarti et al. J Clin Oncol. 2021-05-10;39(14):1600-1601. doi: 10.1200/JCO.21.00027. nihFormattedCitation: Lai SY, Ferris RL. Reply to N. Hirshoren et al and D. Chakrabarti et al. J Clin Oncol. 2021;39(14):1600-1601.. PubMed PMID: 33705206.
Tarhini AA, Kang N, Lee SJ, Hodi FS, Cohen GI, Hamid O, Hutchins LF, Sosman JA, Kluger HM, Eroglu Z, Koon HB, Lawrence DP, Kendra KL, Minor DR, Lee CB, Albertini MR, Flaherty LE, Petrella TM, Streicher H, Sondak VK, Kirkwood JM. Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis. J Immunother Cancer. 2021-05-01;9(5): doi: 10.1136/jitc-2021-002535. nihFormattedCitation: Tarhini AA, Kang N, Lee SJ, Hodi FS, Cohen GI, Hamid O, Hutchins LF, Sosman JA, Kluger HM, Eroglu Z, Koon HB, Lawrence DP, Kendra KL, Minor DR, Lee CB, Albertini MR, Flaherty LE, Petrella TM, Streicher H, Sondak VK, Kirkwood JM. Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis. J Immunother Cancer. 2021;9(5). PMCID: PMC8108687.. PubMed PMID: 33963015; PMCID: PMC8108687.
Zandberg DP, Menk AV, Velez M, Normolle D, DePeaux K, Liu A, Ferris RL, Delgoffe GM. Tumor hypoxia is associated with resistance to PD-1 blockade in squamous cell carcinoma of the head and neck. J Immunother Cancer. 2021-05-01;9(5): doi: 10.1136/jitc-2020-002088. nihFormattedCitation: Zandberg DP, Menk AV, Velez M, Normolle D, DePeaux K, Liu A, Ferris RL, Delgoffe GM. Tumor hypoxia is associated with resistance to PD-1 blockade in squamous cell carcinoma of the head and neck. J Immunother Cancer. 2021;9(5). PMCID: PMC8126285.. PubMed PMID: 33986123; PMCID: PMC8126285.
Scharping NE, Rivadeneira DB, Menk AV, Vignali PDA, Ford BR, Rittenhouse NL, Peralta R, Wang Y, Wang Y, DePeaux K, Poholek AC, Delgoffe GM. Mitochondrial stress induced by continuous stimulation under hypoxia rapidly drives T cell exhaustion. Nat Immunol. 2021-02-01;22(2):205-215. doi: 10.1038/s41590-020-00834-9. nihFormattedCitation: Scharping NE, Rivadeneira DB, Menk AV, Vignali PDA, Ford BR, Rittenhouse NL, Peralta R, Wang Y, Wang Y, DePeaux K, Poholek AC, Delgoffe GM. Mitochondrial stress induced by continuous stimulation under hypoxia rapidly drives T cell exhaustion. Nat Immunol. 2021;22(2):205-215. PMCID: PMC7971090.. PubMed PMID: 33398183; PMCID: PMC7971090.
Luke JJ, Barlesi F, Chung K, Tolcher AW, Kelly K, Hollebecque A, Le Tourneau C, Subbiah V, Tsai F, Kao S, Cassier PA, Khasraw M, Kindler HL, Fang H, Fan F, Allaire K, Patel M, Ye S, Chao DT, Henner WR, Hayflick JS, McDevitt MA, Fong L. Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors. J Immunother Cancer. 2021-02-01;9(2): doi: 10.1136/jitc-2020-002015. nihFormattedCitation: Luke JJ, Barlesi F, Chung K, Tolcher AW, Kelly K, Hollebecque A, Le Tourneau C, Subbiah V, Tsai F, Kao S, Cassier PA, Khasraw M, Kindler HL, Fang H, Fan F, Allaire K, Patel M, Ye S, Chao DT, Henner WR, Hayflick JS, McDevitt MA, Fong L. Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors. J Immunother Cancer. 2021;9(2). PMCID: PMC7898862.. PubMed PMID: 33608377; PMCID: PMC7898862.
Chelvanambi M, Fecek RJ, Taylor JL, Storkus WJ. STING agonist-based treatment promotes vascular normalization and tertiary lymphoid structure formation in the therapeutic melanoma microenvironment. J Immunother Cancer. 2021-02-01;9(2): doi: 10.1136/jitc-2020-001906. nihFormattedCitation: Chelvanambi M, Fecek RJ, Taylor JL, Storkus WJ. STING agonist-based treatment promotes vascular normalization and tertiary lymphoid structure formation in the therapeutic melanoma microenvironment. J Immunother Cancer. 2021;9(2). PMCID: PMC7852948.. PubMed PMID: 33526609; PMCID: PMC7852948.
McPherson AC, Pandey SP, Bender MJ, Meisel M. Systemic Immunoregulatory Consequences of Gut Commensal Translocation. Trends Immunol. 2021-02-01;42(2):137-150. doi: 10.1016/j.it.2020.12.005. nihFormattedCitation: McPherson AC, Pandey SP, Bender MJ, Meisel M. Systemic Immunoregulatory Consequences of Gut Commensal Translocation. Trends Immunol. 2021;42(2):137-150. PMCID: PMC10110348.. PubMed PMID: 33422410; PMCID: PMC10110348.
Burke KP, Grebinoski S, Sharpe AH, Vignali DAA. Understanding adverse events of immunotherapy: A mechanistic perspective. J Exp Med. 2021-01-04;218(1): doi: 10.1084/jem.20192179. nihFormattedCitation: Burke KP, Grebinoski S, Sharpe AH, Vignali DAA. Understanding adverse events of immunotherapy: A mechanistic perspective. J Exp Med. 2021;218(1). PMCID: PMC7754677.. PubMed PMID: 33601411; PMCID: PMC7754677.
Luke JJ, Onderdonk BE, Bhave SR, Karrison T, Lemons JM, Chang P, Zha Y, Carll T, Krausz T, Huang L, Martinez C, Janisch LA, Hseu RD, Moroney JW, Patel JD, Khodarev NN, Salama JK, Ott PA, Fleming GF, Gajewski TF, Weichselbaum RR, Pitroda SP, Chmura SJ. Improved Survival Associated with Local Tumor Response Following Multisite Radiotherapy and Pembrolizumab: Secondary Analysis of a Phase I Trial. Clin Cancer Res. 2020-12-15;26(24):6437-6444. doi: 10.1158/1078-0432.CCR-20-1790. nihFormattedCitation: Luke JJ, Onderdonk BE, Bhave SR, Karrison T, Lemons JM, Chang P, Zha Y, Carll T, Krausz T, Huang L, Martinez C, Janisch LA, Hseu RD, Moroney JW, Patel JD, Khodarev NN, Salama JK, Ott PA, Fleming GF, Gajewski TF, Weichselbaum RR, Pitroda SP, Chmura SJ. Improved Survival Associated with Local Tumor Response Following Multisite Radiotherapy and Pembrolizumab: Secondary Analysis of a Phase I Trial. Clin Cancer Res. 2020;26(24):6437-6444. PMCID: PMC8561652.. PubMed PMID: 33028595; PMCID: PMC8561652.
Rohatgi A, Kirkwood JM. Cancer vaccine induces potent T cell responses - but is it enough? Nat Rev Clin Oncol. 2020-12-01;17(12):721-722. doi: 10.1038/s41571-020-00437-1. nihFormattedCitation: Rohatgi A, Kirkwood JM. Cancer vaccine induces potent T cell responses - but is it enough? Nat Rev Clin Oncol. 2020;17(12):721-722.. PubMed PMID: 32978607.
Lai SY, Ferris RL. Evolving Evidence in Support of Sentinel Lymph Node Biopsy for Early-Stage Oral Cavity Cancer. J Clin Oncol. 2020-12-01;38(34):3983-3986. doi: 10.1200/JCO.20.02716. nihFormattedCitation: Lai SY, Ferris RL. Evolving Evidence in Support of Sentinel Lymph Node Biopsy for Early-Stage Oral Cavity Cancer. J Clin Oncol. 2020;38(34):3983-3986.. PubMed PMID: 33052758.
Whiteside TL. Validation of plasma-derived small extracellular vesicles as cancer biomarkers. Nat Rev Clin Oncol. 2020-12-01;17(12):719-720. doi: 10.1038/s41571-020-00433-5. nihFormattedCitation: Whiteside TL. Validation of plasma-derived small extracellular vesicles as cancer biomarkers. Nat Rev Clin Oncol. 2020;17(12):719-720.. PubMed PMID: 32943766.
Siller M, Zeng Y, Hinterleitner R. Can Microbes Boost Tregs to Suppress Food Sensitivities? Trends Immunol. 2020-11-01;41(11):967-971. doi: 10.1016/j.it.2020.09.005. nihFormattedCitation: Siller M, Zeng Y, Hinterleitner R. Can Microbes Boost Tregs to Suppress Food Sensitivities? Trends Immunol. 2020;41(11):967-971.. PubMed PMID: 33036909.
Chauvin JM, Ka M, Pagliano O, Menna C, Ding Q, DeBlasio R, Sanders C, Hou J, Li XY, Ferrone S, Davar D, Kirkwood JM, Johnston RJ, Korman AJ, Smyth MJ, Zarour HM. IL15 Stimulation with TIGIT Blockade Reverses CD155-mediated NK-Cell Dysfunction in Melanoma. Clin Cancer Res. 2020-10-15;26(20):5520-5533. doi: 10.1158/1078-0432.CCR-20-0575. nihFormattedCitation: Chauvin JM, Ka M, Pagliano O, Menna C, Ding Q, DeBlasio R, Sanders C, Hou J, Li XY, Ferrone S, Davar D, Kirkwood JM, Johnston RJ, Korman AJ, Smyth MJ, Zarour HM. IL15 Stimulation with TIGIT Blockade Reverses CD155-mediated NK-Cell Dysfunction in Melanoma. Clin Cancer Res. 2020;26(20):5520-5533. PMCID: PMC8045409.. PubMed PMID: 32591463; PMCID: PMC8045409.
Gaydosik AM, Queen DS, Trager MH, Akilov OE, Geskin LJ, Fuschiotti P. Genome-wide transcriptome analysis of the STAT6-regulated genes in advanced-stage cutaneous T-cell lymphoma. Blood. 2020-10-08;136(15):1748-1759. doi: 10.1182/blood.2019004725. nihFormattedCitation: Gaydosik AM, Queen DS, Trager MH, Akilov OE, Geskin LJ, Fuschiotti P. Genome-wide transcriptome analysis of the STAT6-regulated genes in advanced-stage cutaneous T-cell lymphoma. Blood. 2020;136(15):1748-1759. PMCID: PMC7544545.. PubMed PMID: 32438399; PMCID: PMC7544545.
Emens LA, Esteva FJ, Beresford M, Saura C, De Laurentiis M, Kim SB, Im SA, Wang Y, Salgado R, Mani A, Shah J, Lambertini C, Liu H, de Haas SL, Patre M, Loi S. Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial. Lancet Oncol. 2020-10-01;21(10):1283-1295. doi: 10.1016/S1470-2045(20)30465-4. nihFormattedCitation: Emens LA, Esteva FJ, Beresford M, Saura C, De Laurentiis M, Kim SB, Im SA, Wang Y, Salgado R, Mani A, Shah J, Lambertini C, Liu H, de Haas SL, Patre M, Loi S. Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial. Lancet Oncol. 2020;21(10):1283-1295.. PubMed PMID: 33002436.
Filderman JN, Storkus WJ. Neoepitopes as Difference Makers for General Cancer Vaccines? Clin Cancer Res. 2020-09-01;26(17):4429-4431. doi: 10.1158/1078-0432.CCR-20-2127. nihFormattedCitation: Filderman JN, Storkus WJ. Neoepitopes as Difference Makers for General Cancer Vaccines? Clin Cancer Res. 2020;26(17):4429-4431. PMCID: PMC7484287.. PubMed PMID: 32646923; PMCID: PMC7484287.
Liu C, Somasundaram A, Manne S, Gocher AM, Szymczak-Workman AL, Vignali KM, Scott EN, Normolle DP, John Wherry E, Lipson EJ, Ferris RL, Bruno TC, Workman CJ, Vignali DAA. Neuropilin-1 is a T cell memory checkpoint limiting long-term antitumor immunity. Nat Immunol. 2020-09-01;21(9):1010-1021. doi: 10.1038/s41590-020-0733-2. nihFormattedCitation: Liu C, Somasundaram A, Manne S, Gocher AM, Szymczak-Workman AL, Vignali KM, Scott EN, Normolle DP, John Wherry E, Lipson EJ, Ferris RL, Bruno TC, Workman CJ, Vignali DAA. Neuropilin-1 is a T cell memory checkpoint limiting long-term antitumor immunity. Nat Immunol. 2020;21(9):1010-1021. PMCID: PMC7442600.. PubMed PMID: 32661362; PMCID: PMC7442600.
Chauvin JM, Zarour HM. TIGIT in cancer immunotherapy. J Immunother Cancer. 2020-09-01;8(2): doi: 10.1136/jitc-2020-000957. nihFormattedCitation: Chauvin JM, Zarour HM. TIGIT in cancer immunotherapy. J Immunother Cancer. 2020;8(2). PMCID: PMC7477968.. PubMed PMID: 32900861; PMCID: PMC7477968.
Zhou M, Sacirbegovic F, Zhao K, Rosenberger S, Shlomchik WD. T cell exhaustion and a failure in antigen presentation drive resistance to the graft-versus-leukemia effect. Nat Commun. 2020-08-24;11(1):4227. doi: 10.1038/s41467-020-17991-y. nihFormattedCitation: Zhou M, Sacirbegovic F, Zhao K, Rosenberger S, Shlomchik WD. T cell exhaustion and a failure in antigen presentation drive resistance to the graft-versus-leukemia effect. Nat Commun. 2020;11(1):4227. PMCID: PMC7445289.. PubMed PMID: 32839441; PMCID: PMC7445289.
Shoushtari AN, Bao R, Luke JJ. PD-1 Blockade in Chinese versus Western Patients with Melanoma. Clin Cancer Res. 2020-08-15;26(16):4171-4173. doi: 10.1158/1078-0432.CCR-20-1558. nihFormattedCitation: Shoushtari AN, Bao R, Luke JJ. PD-1 Blockade in Chinese versus Western Patients with Melanoma. Clin Cancer Res. 2020;26(16):4171-4173. PMCID: PMC7442612.. PubMed PMID: 32487680; PMCID: PMC7442612.
Garris CS, Luke JJ. Dendritic Cells, the T-cell-inflamed Tumor Microenvironment, and Immunotherapy Treatment Response. Clin Cancer Res. 2020-08-01;26(15):3901-3907. doi: 10.1158/1078-0432.CCR-19-1321. nihFormattedCitation: Garris CS, Luke JJ. Dendritic Cells, the T-cell-inflamed Tumor Microenvironment, and Immunotherapy Treatment Response. Clin Cancer Res. 2020;26(15):3901-3907. PMCID: PMC7607412.. PubMed PMID: 32332013; PMCID: PMC7607412.
Zeh HJ, Bahary N, Boone BA, Singhi AD, Miller-Ocuin JL, Normolle DP, Zureikat AH, Hogg ME, Bartlett DL, Lee KK, Tsung A, Marsh JW, Murthy P, Tang D, Seiser N, Amaravadi RK, Espina V, Liotta L, Lotze MT. A Randomized Phase II Preoperative Study of Autophagy Inhibition with High-Dose Hydroxychloroquine and Gemcitabine/Nab-Paclitaxel in Pancreatic Cancer Patients. Clin Cancer Res. 2020-07-01;26(13):3126-3134. doi: 10.1158/1078-0432.CCR-19-4042. nihFormattedCitation: Zeh HJ, Bahary N, Boone BA, Singhi AD, Miller-Ocuin JL, Normolle DP, Zureikat AH, Hogg ME, Bartlett DL, Lee KK, Tsung A, Marsh JW, Murthy P, Tang D, Seiser N, Amaravadi RK, Espina V, Liotta L, Lotze MT. A Randomized Phase II Preoperative Study of Autophagy Inhibition with High-Dose Hydroxychloroquine and Gemcitabine/Nab-Paclitaxel in Pancreatic Cancer Patients. Clin Cancer Res. 2020;26(13):3126-3134. PMCID: PMC8086597.. PubMed PMID: 32156749; PMCID: PMC8086597.
Bao R, Hernandez K, Huang L, Luke JJ. ACE2 and TMPRSS2 expression by clinical, HLA, immune, and microbial correlates across 34 human cancers and matched normal tissues: implications for SARS-CoV-2 COVID-19. J Immunother Cancer. 2020-07-01;8(2): doi: 10.1136/jitc-2020-001020. nihFormattedCitation: Bao R, Hernandez K, Huang L, Luke JJ. ACE2 and TMPRSS2 expression by clinical, HLA, immune, and microbial correlates across 34 human cancers and matched normal tissues: implications for SARS-CoV-2 COVID-19. J Immunother Cancer. 2020;8(2). PMCID: PMC7372174.. PubMed PMID: 32675312; PMCID: PMC7372174.
Chuckran CA, Liu C, Bruno TC, Workman CJ, Vignali DA. Neuropilin-1: a checkpoint target with unique implications for cancer immunology and immunotherapy. J Immunother Cancer. 2020-07-01;8(2): doi: 10.1136/jitc-2020-000967. nihFormattedCitation: Chuckran CA, Liu C, Bruno TC, Workman CJ, Vignali DA. Neuropilin-1: a checkpoint target with unique implications for cancer immunology and immunotherapy. J Immunother Cancer. 2020;8(2). PMCID: PMC7368550.. PubMed PMID: 32675311; PMCID: PMC7368550.
Tilstra JS, John S, Gordon RA, Leibler C, Kashgarian M, Bastacky S, Nickerson KM, Shlomchik MJ. B cell-intrinsic TLR9 expression is protective in murine lupus. J Clin Invest. 2020-06-01;130(6):3172-3187. doi: 10.1172/JCI132328. nihFormattedCitation: Tilstra JS, John S, Gordon RA, Leibler C, Kashgarian M, Bastacky S, Nickerson KM, Shlomchik MJ. B cell-intrinsic TLR9 expression is protective in murine lupus. J Clin Invest. 2020;130(6):3172-3187. PMCID: PMC7260024.. PubMed PMID: 32191633; PMCID: PMC7260024.
Somasundaram A, Socinski MA, Villaruz LC. Immune Checkpoint Blockade in Oncogene-Driven Non-Small-Cell Lung Cancer. Drugs. 2020-06-01;80(9):883-892. doi: 10.1007/s40265-020-01320-0. nihFormattedCitation: Somasundaram A, Socinski MA, Villaruz LC. Immune Checkpoint Blockade in Oncogene-Driven Non-Small-Cell Lung Cancer. Drugs. 2020;80(9):883-892. PMCID: PMC8579493.. PubMed PMID: 32436070; PMCID: PMC8579493.
Najjar YG, Navrazhina K, Ding F, Bhatia R, Tsai K, Abbate K, Durden B, Eroglu Z, Bhatia S, Park S, Chowdhary A, Chandra S, Kennedy J, Puzanov I, Ernstoff M, Vachhani P, Drabick J, Singh A, Xu T, Yang J, Carvajal R, Manson D, Kirkwood JM, Cohen J, Sullivan R, Johnson D, Funchain P, Shoushtari A. Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study. J Immunother Cancer. 2020-06-01;8(1): doi: 10.1136/jitc-2019-000331. nihFormattedCitation: Najjar YG, Navrazhina K, Ding F, Bhatia R, Tsai K, Abbate K, Durden B, Eroglu Z, Bhatia S, Park S, Chowdhary A, Chandra S, Kennedy J, Puzanov I, Ernstoff M, Vachhani P, Drabick J, Singh A, Xu T, Yang J, Carvajal R, Manson D, Kirkwood JM, Cohen J, Sullivan R, Johnson D, Funchain P, Shoushtari A. Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study. J Immunother Cancer. 2020;8(1). PMCID: PMC7319717.. PubMed PMID: 32581057; PMCID: PMC7319717.
Luke JJ, Ascierto PA. Biology confirmed but biomarkers elusive in melanoma immunotherapy. Nat Rev Clin Oncol. 2020-04-01;17(4):198-199. doi: 10.1038/s41571-020-0328-8. nihFormattedCitation: Luke JJ, Ascierto PA. Biology confirmed but biomarkers elusive in melanoma immunotherapy. Nat Rev Clin Oncol. 2020;17(4):198-199.. PubMed PMID: 31974501.
Weisel FJ, Mullett SJ, Elsner RA, Menk AV, Trivedi N, Luo W, Wikenheiser D, Hawse WF, Chikina M, Smita S, Conter LJ, Joachim SM, Wendell SG, Jurczak MJ, Winkler TH, Delgoffe GM, Shlomchik MJ. Germinal center B cells selectively oxidize fatty acids for energy while conducting minimal glycolysis. Nat Immunol. 2020-03-01;21(3):331-342. doi: 10.1038/s41590-020-0598-4. nihFormattedCitation: Weisel FJ, Mullett SJ, Elsner RA, Menk AV, Trivedi N, Luo W, Wikenheiser D, Hawse WF, Chikina M, Smita S, Conter LJ, Joachim SM, Wendell SG, Jurczak MJ, Winkler TH, Delgoffe GM, Shlomchik MJ. Germinal center B cells selectively oxidize fatty acids for energy while conducting minimal glycolysis. Nat Immunol. 2020;21(3):331-342. PMCID: PMC7112716.. PubMed PMID: 32066950; PMCID: PMC7112716.
Tarhini AA, Lee SJ, Hodi FS, Rao UNM, Cohen GI, Hamid O, Hutchins LF, Sosman JA, Kluger HM, Eroglu Z, Koon HB, Lawrence DP, Kendra KL, Minor DR, Lee CB, Albertini MR, Flaherty LE, Petrella TM, Streicher H, Sondak VK, Kirkwood JM. Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609. J Clin Oncol. 2020-02-20;38(6):567-575. doi: 10.1200/JCO.19.01381. nihFormattedCitation: Tarhini AA, Lee SJ, Hodi FS, Rao UNM, Cohen GI, Hamid O, Hutchins LF, Sosman JA, Kluger HM, Eroglu Z, Koon HB, Lawrence DP, Kendra KL, Minor DR, Lee CB, Albertini MR, Flaherty LE, Petrella TM, Streicher H, Sondak VK, Kirkwood JM. Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609. J Clin Oncol. 2020;38(6):567-575. PMCID: PMC7030886.. PubMed PMID: 31880964; PMCID: PMC7030886.
Luke JJ, Olson DJ, Allred JB, Strand CA, Bao R, Zha Y, Carll T, Labadie BW, Bastos BR, Butler MO, Hogg D, Munster PN, Schwartz GK. Randomized Phase II Trial and Tumor Mutational Spectrum Analysis from Cabozantinib versus Chemotherapy in Metastatic Uveal Melanoma (Alliance A091201). Clin Cancer Res. 2020-02-15;26(4):804-811. doi: 10.1158/1078-0432.CCR-19-1223. nihFormattedCitation: Luke JJ, Olson DJ, Allred JB, Strand CA, Bao R, Zha Y, Carll T, Labadie BW, Bastos BR, Butler MO, Hogg D, Munster PN, Schwartz GK. Randomized Phase II Trial and Tumor Mutational Spectrum Analysis from Cabozantinib versus Chemotherapy in Metastatic Uveal Melanoma (Alliance A091201). Clin Cancer Res. 2020;26(4):804-811. PMCID: PMC7055933.. PubMed PMID: 31558480; PMCID: PMC7055933.
Cillo AR, Kürten CHL, Tabib T, Qi Z, Onkar S, Wang T, Liu A, Duvvuri U, Kim S, Soose RJ, Oesterreich S, Chen W, Lafyatis R, Bruno TC, Ferris RL, Vignali DAA. Immune Landscape of Viral- and Carcinogen-Driven Head and Neck Cancer. Immunity. 2020-01-14;52(1):183-199.e9. doi: 10.1016/j.immuni.2019.11.014. nihFormattedCitation: Cillo AR, Kürten CHL, Tabib T, Qi Z, Onkar S, Wang T, Liu A, Duvvuri U, Kim S, Soose RJ, Oesterreich S, Chen W, Lafyatis R, Bruno TC, Ferris RL, Vignali DAA. Immune Landscape of Viral- and Carcinogen-Driven Head and Neck Cancer. Immunity. 2020;52(1):183-199.e9. PMCID: PMC7201194.. PubMed PMID: 31924475; PMCID: PMC7201194.
Balmert SC, Carey CD, Falo GD, Sethi SK, Erdos G, Korkmaz E, Falo LD Jr. Dissolving undercut microneedle arrays for multicomponent cutaneous vaccination. J Control Release. 2020-01-10;317336-346. doi: 10.1016/j.jconrel.2019.11.023. nihFormattedCitation: Balmert SC, Carey CD, Falo GD, Sethi SK, Erdos G, Korkmaz E, Falo LD Jr. Dissolving undercut microneedle arrays for multicomponent cutaneous vaccination. J Control Release. 2020;317:336-346. PMCID: PMC8237702.. PubMed PMID: 31756393; PMCID: PMC8237702.
Trivedi N, Weisel F, Smita S, Joachim S, Kader M, Radhakrishnan A, Clouser C, Rosenfeld AM, Chikina M, Vigneault F, Hershberg U, Ismail N, Shlomchik MJ. Liver Is a Generative Site for the B Cell Response to Ehrlichia muris. Immunity. 2019-12-17;51(6):1088-1101.e5. doi: 10.1016/j.immuni.2019.10.004. nihFormattedCitation: Trivedi N, Weisel F, Smita S, Joachim S, Kader M, Radhakrishnan A, Clouser C, Rosenfeld AM, Chikina M, Vigneault F, Hershberg U, Ismail N, Shlomchik MJ. Liver Is a Generative Site for the B Cell Response to Ehrlichia muris. Immunity. 2019;51(6):1088-1101.e5. PMCID: PMC6955021.. PubMed PMID: 31732168; PMCID: PMC6955021.
Ferris RL, Licitra L. PD-1 immunotherapy for recurrent or metastatic HNSCC. Lancet. 2019-11-23;394(10212):1882-1884. doi: 10.1016/S0140-6736(19)32539-5. nihFormattedCitation: Ferris RL, Licitra L. PD-1 immunotherapy for recurrent or metastatic HNSCC. Lancet. 2019;394(10212):1882-1884.. PubMed PMID: 31679948.
Andrews LP, Yano H, Vignali DAA. Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups. Nat Immunol. 2019-11-01;20(11):1425-1434. doi: 10.1038/s41590-019-0512-0. nihFormattedCitation: Andrews LP, Yano H, Vignali DAA. Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups. Nat Immunol. 2019;20(11):1425-1434.. PubMed PMID: 31611702.
Cramer JD, Burtness B, Le QT, Ferris RL. The changing therapeutic landscape of head and neck cancer. Nat Rev Clin Oncol. 2019-11-01;16(11):669-683. doi: 10.1038/s41571-019-0227-z. nihFormattedCitation: Cramer JD, Burtness B, Le QT, Ferris RL. The changing therapeutic landscape of head and neck cancer. Nat Rev Clin Oncol. 2019;16(11):669-683.. PubMed PMID: 31189965.
Molinero L, Li Y, Chang CW, Maund S, Berg M, Harrison J, Fassò M, O'Hear C, Hegde P, Emens LA. Tumor immune microenvironment and genomic evolution in a patient with metastatic triple negative breast cancer and a complete response to atezolizumab. J Immunother Cancer. 2019-10-23;7(1):274. doi: 10.1186/s40425-019-0740-8. nihFormattedCitation: Molinero L, Li Y, Chang CW, Maund S, Berg M, Harrison J, Fassò M, O'Hear C, Hegde P, Emens LA. Tumor immune microenvironment and genomic evolution in a patient with metastatic triple negative breast cancer and a complete response to atezolizumab. J Immunother Cancer. 2019;7(1):274. PMCID: PMC6813065.. PubMed PMID: 31647026; PMCID: PMC6813065.
Rivadeneira DB, DePeaux K, Wang Y, Kulkarni A, Tabib T, Menk AV, Sampath P, Lafyatis R, Ferris RL, Sarkar SN, Thorne SH, Delgoffe GM. Oncolytic Viruses Engineered to Enforce Leptin Expression Reprogram Tumor-Infiltrating T Cell Metabolism and Promote Tumor Clearance. Immunity. 2019-09-17;51(3):548-560.e4. doi: 10.1016/j.immuni.2019.07.003. nihFormattedCitation: Rivadeneira DB, DePeaux K, Wang Y, Kulkarni A, Tabib T, Menk AV, Sampath P, Lafyatis R, Ferris RL, Sarkar SN, Thorne SH, Delgoffe GM. Oncolytic Viruses Engineered to Enforce Leptin Expression Reprogram Tumor-Infiltrating T Cell Metabolism and Promote Tumor Clearance. Immunity. 2019;51(3):548-560.e4. PMCID: PMC6903394.. PubMed PMID: 31471106; PMCID: PMC6903394.
Ferris RL, Licitra L, Fayette J, Even C, Blumenschein G Jr, Harrington KJ, Guigay J, Vokes EE, Saba NF, Haddad R, Ramkumar S, Russell J, Brossart P, Tahara M, Colevas AD, Concha-Benavente F, Lynch M, Li L, Gillison ML. Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use. Clin Cancer Res. 2019-09-01;25(17):5221-5230. doi: 10.1158/1078-0432.CCR-18-3944. nihFormattedCitation: Ferris RL, Licitra L, Fayette J, Even C, Blumenschein G Jr, Harrington KJ, Guigay J, Vokes EE, Saba NF, Haddad R, Ramkumar S, Russell J, Brossart P, Tahara M, Colevas AD, Concha-Benavente F, Lynch M, Li L, Gillison ML. Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use. Clin Cancer Res. 2019;25(17):5221-5230. PMCID: PMC7721346.. PubMed PMID: 31239321; PMCID: PMC7721346.
Liu C, Chikina M, Deshpande R, Menk AV, Wang T, Tabib T, Brunazzi EA, Vignali KM, Sun M, Stolz DB, Lafyatis RA, Chen W, Delgoffe GM, Workman CJ, Wendell SG, Vignali DAA. Treg Cells Promote the SREBP1-Dependent Metabolic Fitness of Tumor-Promoting Macrophages via Repression of CD8(+) T Cell-Derived Interferon-γ. Immunity. 2019-08-20;51(2):381-397.e6. doi: 10.1016/j.immuni.2019.06.017. nihFormattedCitation: Liu C, Chikina M, Deshpande R, Menk AV, Wang T, Tabib T, Brunazzi EA, Vignali KM, Sun M, Stolz DB, Lafyatis RA, Chen W, Delgoffe GM, Workman CJ, Wendell SG, Vignali DAA. Treg Cells Promote the SREBP1-Dependent Metabolic Fitness of Tumor-Promoting Macrophages via Repression of CD8(+) T Cell-Derived Interferon-γ. Immunity. 2019;51(2):381-397.e6. PMCID: PMC6703933.. PubMed PMID: 31350177; PMCID: PMC6703933.
Cohen EEW, Bell RB, Bifulco CB, Burtness B, Gillison ML, Harrington KJ, Le QT, Lee NY, Leidner R, Lewis RL, Licitra L, Mehanna H, Mell LK, Raben A, Sikora AG, Uppaluri R, Whitworth F, Zandberg DP, Ferris RL. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC). J Immunother Cancer. 2019-07-15;7(1):184. doi: 10.1186/s40425-019-0662-5. nihFormattedCitation: Cohen EEW, Bell RB, Bifulco CB, Burtness B, Gillison ML, Harrington KJ, Le QT, Lee NY, Leidner R, Lewis RL, Licitra L, Mehanna H, Mell LK, Raben A, Sikora AG, Uppaluri R, Whitworth F, Zandberg DP, Ferris RL. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC). J Immunother Cancer. 2019;7(1):184. PMCID: PMC6632213.. PubMed PMID: 31307547; PMCID: PMC6632213.
Ferris RL, Cramer JD, Branstetter Iv BF. Positron Emission Tomography/Computed Tomography in Evaluation of the Clinically N0 Neck in Head and Neck Squamous Cell Carcinoma. J Clin Oncol. 2019-07-10;37(20):1683-1685. doi: 10.1200/JCO.19.00544. nihFormattedCitation: Ferris RL, Cramer JD, Branstetter Iv BF. Positron Emission Tomography/Computed Tomography in Evaluation of the Clinically N0 Neck in Head and Neck Squamous Cell Carcinoma. J Clin Oncol. 2019;37(20):1683-1685. PMCID: PMC6638595.. PubMed PMID: 31150317; PMCID: PMC6638595.
Gopalakrishna KP, Macadangdang BR, Rogers MB, Tometich JT, Firek BA, Baker R, Ji J, Burr AHP, Ma C, Good M, Morowitz MJ, Hand TW. Maternal IgA protects against the development of necrotizing enterocolitis in preterm infants. Nat Med. 2019-07-01;25(7):1110-1115. doi: 10.1038/s41591-019-0480-9. nihFormattedCitation: Gopalakrishna KP, Macadangdang BR, Rogers MB, Tometich JT, Firek BA, Baker R, Ji J, Burr AHP, Ma C, Good M, Morowitz MJ, Hand TW. Maternal IgA protects against the development of necrotizing enterocolitis in preterm infants. Nat Med. 2019;25(7):1110-1115. PMCID: PMC7424541.. PubMed PMID: 31209335; PMCID: PMC7424541.
Davar D, Kirkwood JM. PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: Understanding the Upside of the Downside of Checkpoint Blockade. JAMA Oncol. 2019-07-01;5(7):942-943. doi: 10.1001/jamaoncol.2019.0413. nihFormattedCitation: Davar D, Kirkwood JM. PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: Understanding the Upside of the Downside of Checkpoint Blockade. JAMA Oncol. 2019;5(7):942-943.. PubMed PMID: 31021377.
Sawant DV, Yano H, Chikina M, Zhang Q, Liao M, Liu C, Callahan DJ, Sun Z, Sun T, Tabib T, Pennathur A, Corry DB, Luketich JD, Lafyatis R, Chen W, Poholek AC, Bruno TC, Workman CJ, Vignali DAA. Adaptive plasticity of IL-10(+) and IL-35(+) T(reg) cells cooperatively promotes tumor T cell exhaustion. Nat Immunol. 2019-06-01;20(6):724-735. doi: 10.1038/s41590-019-0346-9. nihFormattedCitation: Sawant DV, Yano H, Chikina M, Zhang Q, Liao M, Liu C, Callahan DJ, Sun Z, Sun T, Tabib T, Pennathur A, Corry DB, Luketich JD, Lafyatis R, Chen W, Poholek AC, Bruno TC, Workman CJ, Vignali DAA. Adaptive plasticity of IL-10(+) and IL-35(+) T(reg) cells cooperatively promotes tumor T cell exhaustion. Nat Immunol. 2019;20(6):724-735. PMCID: PMC6531353.. PubMed PMID: 30936494; PMCID: PMC6531353.
Luo W, Hawse W, Conter L, Trivedi N, Weisel F, Wikenheiser D, Cattley RT, Shlomchik MJ. The AKT kinase signaling network is rewired by PTEN to control proximal BCR signaling in germinal center B cells. Nat Immunol. 2019-06-01;20(6):736-746. doi: 10.1038/s41590-019-0376-3. nihFormattedCitation: Luo W, Hawse W, Conter L, Trivedi N, Weisel F, Wikenheiser D, Cattley RT, Shlomchik MJ. The AKT kinase signaling network is rewired by PTEN to control proximal BCR signaling in germinal center B cells. Nat Immunol. 2019;20(6):736-746. PMCID: PMC6724213.. PubMed PMID: 31011187; PMCID: PMC6724213.
Shurin GV, Kruglov O, Ding F, Lin Y, Hao X, Keskinov AA, You Z, Lokshin AE, LaFramboise WA, Falo LD Jr, Shurin MR, Bunimovich YL. Melanoma-Induced Reprogramming of Schwann Cell Signaling Aids Tumor Growth. Cancer Res. 2019-05-15;79(10):2736-2747. doi: 10.1158/0008-5472.CAN-18-3872. nihFormattedCitation: Shurin GV, Kruglov O, Ding F, Lin Y, Hao X, Keskinov AA, You Z, Lokshin AE, LaFramboise WA, Falo LD Jr, Shurin MR, Bunimovich YL. Melanoma-Induced Reprogramming of Schwann Cell Signaling Aids Tumor Growth. Cancer Res. 2019;79(10):2736-2747. PMCID: PMC6522315.. PubMed PMID: 30914431; PMCID: PMC6522315.
Butterfield LH, Vujanovic L, Santos PM, Maurer DM, Gambotto A, Lohr J, Li C, Waldman J, Chandran U, Lin Y, Lin H, Tawbi HA, Tarhini AA, Kirkwood JM. Multiple antigen-engineered DC vaccines with or without IFNα to promote antitumor immunity in melanoma. J Immunother Cancer. 2019-04-24;7(1):113. doi: 10.1186/s40425-019-0552-x. nihFormattedCitation: Butterfield LH, Vujanovic L, Santos PM, Maurer DM, Gambotto A, Lohr J, Li C, Waldman J, Chandran U, Lin Y, Lin H, Tawbi HA, Tarhini AA, Kirkwood JM. Multiple antigen-engineered DC vaccines with or without IFNα to promote antitumor immunity in melanoma. J Immunother Cancer. 2019;7(1):113. PMCID: PMC6480917.. PubMed PMID: 31014399; PMCID: PMC6480917.
Donnenberg AD, Luketich JD, Dhupar R, Donnenberg VS. Treatment of malignant pleural effusions: the case for localized immunotherapy. J Immunother Cancer. 2019-04-18;7(1):110. doi: 10.1186/s40425-019-0590-4. nihFormattedCitation: Donnenberg AD, Luketich JD, Dhupar R, Donnenberg VS. Treatment of malignant pleural effusions: the case for localized immunotherapy. J Immunother Cancer. 2019;7(1):110. PMCID: PMC6472034.. PubMed PMID: 30999958; PMCID: PMC6472034.
Tarhini AA, Lee SJ, Li X, Rao UNM, Nagarajan A, Albertini MR, Mitchell JW Jr, Wong SJ, Taylor MA, Laudi N, Truong PV, Conry RM, Kirkwood JM. E3611-A Randomized Phase II Study of Ipilimumab at 3 or 10 mg/kg Alone or in Combination with High-Dose Interferon-α2b in Advanced Melanoma. Clin Cancer Res. 2019-01-15;25(2):524-532. doi: 10.1158/1078-0432.CCR-18-2258. nihFormattedCitation: Tarhini AA, Lee SJ, Li X, Rao UNM, Nagarajan A, Albertini MR, Mitchell JW Jr, Wong SJ, Taylor MA, Laudi N, Truong PV, Conry RM, Kirkwood JM. E3611-A Randomized Phase II Study of Ipilimumab at 3 or 10 mg/kg Alone or in Combination with High-Dose Interferon-α2b in Advanced Melanoma. Clin Cancer Res. 2019;25(2):524-532. PMCID: PMC6335150.. PubMed PMID: 30420448; PMCID: PMC6335150.
Emens LA, Cruz C, Eder JP, Braiteh F, Chung C, Tolaney SM, Kuter I, Nanda R, Cassier PA, Delord JP, Gordon MS, ElGabry E, Chang CW, Sarkar I, Grossman W, O'Hear C, Fassò M, Molinero L, Schmid P. Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer: A Phase 1 Study. JAMA Oncol. 2019-01-01;5(1):74-82. doi: 10.1001/jamaoncol.2018.4224. nihFormattedCitation: Emens LA, Cruz C, Eder JP, Braiteh F, Chung C, Tolaney SM, Kuter I, Nanda R, Cassier PA, Delord JP, Gordon MS, ElGabry E, Chang CW, Sarkar I, Grossman W, O'Hear C, Fassò M, Molinero L, Schmid P. Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer: A Phase 1 Study. JAMA Oncol. 2019;5(1):74-82. PMCID: PMC6439773.. PubMed PMID: 30242306; PMCID: PMC6439773.
Butterfield LH, Disis ML, Fox BA, Kaufman DR, Khleif SN, Wang E, Society for Immunotherapy of Cancer Immuno-Oncology Biomarkers: State of the Art workshop speakers. SITC 2018 workshop report: Immuno-Oncology Biomarkers: State of the Art. J Immunother Cancer. 2018-12-04;6(1):138. doi: 10.1186/s40425-018-0453-4. nihFormattedCitation: Butterfield LH, Disis ML, Fox BA, Kaufman DR, Khleif SN, Wang E, Society for Immunotherapy of Cancer Immuno-Oncology Biomarkers: State of the Art workshop speakers. SITC 2018 workshop report: Immuno-Oncology Biomarkers: State of the Art. J Immunother Cancer. 2018;6(1):138. PMCID: PMC6278162.. PubMed PMID: 30514399; PMCID: PMC6278162.
Uche UU, Piccirillo AR, Kataoka S, Grebinoski SJ, D'Cruz LM, Kane LP. PIK3IP1/TrIP restricts activation of T cells through inhibition of PI3K/Akt. J Exp Med. 2018-12-03;215(12):3165-3179. doi: 10.1084/jem.20172018. nihFormattedCitation: Uche UU, Piccirillo AR, Kataoka S, Grebinoski SJ, D'Cruz LM, Kane LP. PIK3IP1/TrIP restricts activation of T cells through inhibition of PI3K/Akt. J Exp Med. 2018;215(12):3165-3179. PMCID: PMC6279406.. PubMed PMID: 30429249; PMCID: PMC6279406.
Santos PM, Butterfield LH. Next Steps for Immune Checkpoints in Hepatocellular Carcinoma. Gastroenterology. 2018-12-01;155(6):1684-1686. doi: 10.1053/j.gastro.2018.11.008. nihFormattedCitation: Santos PM, Butterfield LH. Next Steps for Immune Checkpoints in Hepatocellular Carcinoma. Gastroenterology. 2018;155(6):1684-1686.. PubMed PMID: 30419214.
Ferris RL, Saba NF, Gitlitz BJ, Haddad R, Sukari A, Neupane P, Morris JC, Misiukiewicz K, Bauman JE, Fenton M, Jimeno A, Adkins DR, Schneider CJ, Sacco AG, Shirai K, Bowles DW, Gibson M, Nwizu T, Gottardo R, Manjarrez KL, Dietsch GN, Bryan JK, Hershberg RM, Cohen EEW. Effect of Adding Motolimod to Standard Combination Chemotherapy and Cetuximab Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck: The Active8 Randomized Clinical Trial. JAMA Oncol. 2018-11-01;4(11):1583-1588. doi: 10.1001/jamaoncol.2018.1888. nihFormattedCitation: Ferris RL, Saba NF, Gitlitz BJ, Haddad R, Sukari A, Neupane P, Morris JC, Misiukiewicz K, Bauman JE, Fenton M, Jimeno A, Adkins DR, Schneider CJ, Sacco AG, Shirai K, Bowles DW, Gibson M, Nwizu T, Gottardo R, Manjarrez KL, Dietsch GN, Bryan JK, Hershberg RM, Cohen EEW. Effect of Adding Motolimod to Standard Combination Chemotherapy and Cetuximab Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck: The Active8 Randomized Clinical Trial. JAMA Oncol. 2018;4(11):1583-1588. PMCID: PMC6248084.. PubMed PMID: 29931076; PMCID: PMC6248084.
Tilstra JS, Avery L, Menk AV, Gordon RA, Smita S, Kane LP, Chikina M, Delgoffe GM, Shlomchik MJ. Kidney-infiltrating T cells in murine lupus nephritis are metabolically and functionally exhausted. J Clin Invest. 2018-11-01;128(11):4884-4897. doi: 10.1172/JCI120859. nihFormattedCitation: Tilstra JS, Avery L, Menk AV, Gordon RA, Smita S, Kane LP, Chikina M, Delgoffe GM, Shlomchik MJ. Kidney-infiltrating T cells in murine lupus nephritis are metabolically and functionally exhausted. J Clin Invest. 2018;128(11):4884-4897. PMCID: PMC6205402.. PubMed PMID: 30130253; PMCID: PMC6205402.
Davar D, Wang H, Chauvin JM, Pagliano O, Fourcade JJ, Ka M, Menna C, Rose A, Sander C, Borhani AA, Karunamurthy A, Tarhini AA, Tawbi HA, Zhao Q, Moreno BH, Ebbinghaus S, Ibrahim N, Kirkwood JM, Zarour HM. Phase Ib/II Study of Pembrolizumab and Pegylated-Interferon Alfa-2b in Advanced Melanoma. J Clin Oncol. 2018-10-25;36(35):JCO1800632. doi: 10.1200/JCO.18.00632. nihFormattedCitation: Davar D, Wang H, Chauvin JM, Pagliano O, Fourcade JJ, Ka M, Menna C, Rose A, Sander C, Borhani AA, Karunamurthy A, Tarhini AA, Tawbi HA, Zhao Q, Moreno BH, Ebbinghaus S, Ibrahim N, Kirkwood JM, Zarour HM. Phase Ib/II Study of Pembrolizumab and Pegylated-Interferon Alfa-2b in Advanced Melanoma. J Clin Oncol. 2018;36(35):JCO1800632. PMCID: PMC6286160.. PubMed PMID: 30359157; PMCID: PMC6286160.
Tarhini A, Lin Y, Lin H, Rahman Z, Vallabhaneni P, Mendiratta P, Pingpank JF, Holtzman MP, Yusko EC, Rytlewski JA, Rao UNM, Ferris RL, Kirkwood JM. Neoadjuvant ipilimumab (3 mg/kg or 10 mg/kg) and high dose IFN-α2b in locally/regionally advanced melanoma: safety, efficacy and impact on T-cell repertoire. J Immunother Cancer. 2018-10-23;6(1):112. doi: 10.1186/s40425-018-0428-5. nihFormattedCitation: Tarhini A, Lin Y, Lin H, Rahman Z, Vallabhaneni P, Mendiratta P, Pingpank JF, Holtzman MP, Yusko EC, Rytlewski JA, Rao UNM, Ferris RL, Kirkwood JM. Neoadjuvant ipilimumab (3 mg/kg or 10 mg/kg) and high dose IFN-α2b in locally/regionally advanced melanoma: safety, efficacy and impact on T-cell repertoire. J Immunother Cancer. 2018;6(1):112. PMCID: PMC6199801.. PubMed PMID: 30352626; PMCID: PMC6199801.
Zhou Y, Shurin GV, Zhong H, Bunimovich YL, Han B, Shurin MR. Schwann Cells Augment Cell Spreading and Metastasis of Lung Cancer. Cancer Res. 2018-10-15;78(20):5927-5939. doi: 10.1158/0008-5472.CAN-18-1702. nihFormattedCitation: Zhou Y, Shurin GV, Zhong H, Bunimovich YL, Han B, Shurin MR. Schwann Cells Augment Cell Spreading and Metastasis of Lung Cancer. Cancer Res. 2018;78(20):5927-5939.. PubMed PMID: 30135194.
Butterfield LH. The Society for Immunotherapy of Cancer Biomarkers Task Force recommendations review. Semin Cancer Biol. 2018-10-01;52(Pt 2):12-15. doi: 10.1016/j.semcancer.2017.09.006. nihFormattedCitation: Butterfield LH. The Society for Immunotherapy of Cancer Biomarkers Task Force recommendations review. Semin Cancer Biol. 2018;52(Pt 2):12-15. PMCID: PMC5862764.. PubMed PMID: 28943324; PMCID: PMC5862764.
Liu Z, McMichael EL, Shayan G, Li J, Chen K, Srivastava R, Kane LP, Lu B, Ferris RL. Novel Effector Phenotype of Tim-3(+) Regulatory T Cells Leads to Enhanced Suppressive Function in Head and Neck Cancer Patients. Clin Cancer Res. 2018-09-15;24(18):4529-4538. doi: 10.1158/1078-0432.CCR-17-1350. nihFormattedCitation: Liu Z, McMichael EL, Shayan G, Li J, Chen K, Srivastava R, Kane LP, Lu B, Ferris RL. Novel Effector Phenotype of Tim-3(+) Regulatory T Cells Leads to Enhanced Suppressive Function in Head and Neck Cancer Patients. Clin Cancer Res. 2018;24(18):4529-4538. PMCID: PMC6139056.. PubMed PMID: 29712685; PMCID: PMC6139056.
Garcia CA, El-Ali A, Rath TJ, Contis LC, Gorantla V, Drappatz J, Davar D. Neurologic immune-related adverse events associated with adjuvant ipilimumab: report of two cases. J Immunother Cancer. 2018-08-31;6(1):83. doi: 10.1186/s40425-018-0393-z. nihFormattedCitation: Garcia CA, El-Ali A, Rath TJ, Contis LC, Gorantla V, Drappatz J, Davar D. Neurologic immune-related adverse events associated with adjuvant ipilimumab: report of two cases. J Immunother Cancer. 2018;6(1):83. PMCID: PMC6117978.. PubMed PMID: 30170622; PMCID: PMC6117978.
Dreno B, Thompson JF, Smithers BM, Santinami M, Jouary T, Gutzmer R, Levchenko E, Rutkowski P, Grob JJ, Korovin S, Drucis K, Grange F, Machet L, Hersey P, Krajsova I, Testori A, Conry R, Guillot B, Kruit WHJ, Demidov L, Thompson JA, Bondarenko I, Jaroszek J, Puig S, Cinat G, Hauschild A, Goeman JJ, van Houwelingen HC, Ulloa-Montoya F, Callegaro A, Dizier B, Spiessens B, Debois M, Brichard VG, Louahed J, Therasse P, Debruyne C, Kirkwood JM. MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2018-07-01;19(7):916-929. doi: 10.1016/S1470-2045(18)30254-7. nihFormattedCitation: Dreno B, Thompson JF, Smithers BM, Santinami M, Jouary T, Gutzmer R, Levchenko E, Rutkowski P, Grob JJ, Korovin S, Drucis K, Grange F, Machet L, Hersey P, Krajsova I, Testori A, Conry R, Guillot B, Kruit WHJ, Demidov L, Thompson JA, Bondarenko I, Jaroszek J, Puig S, Cinat G, Hauschild A, Goeman JJ, van Houwelingen HC, Ulloa-Montoya F, Callegaro A, Dizier B, Spiessens B, Debois M, Brichard VG, Louahed J, Therasse P, Debruyne C, Kirkwood JM. MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2018;19(7):916-929.. PubMed PMID: 29908991.
Rivadeneira DB, Delgoffe GM. Antitumor T-cell Reconditioning: Improving Metabolic Fitness for Optimal Cancer Immunotherapy. Clin Cancer Res. 2018-06-01;24(11):2473-2481. doi: 10.1158/1078-0432.CCR-17-0894. nihFormattedCitation: Rivadeneira DB, Delgoffe GM. Antitumor T-cell Reconditioning: Improving Metabolic Fitness for Optimal Cancer Immunotherapy. Clin Cancer Res. 2018;24(11):2473-2481. PMCID: PMC5984673.. PubMed PMID: 29386217; PMCID: PMC5984673.
Menk AV, Scharping NE, Rivadeneira DB, Calderon MJ, Watson MJ, Dunstane D, Watkins SC, Delgoffe GM. 4-1BB costimulation induces T cell mitochondrial function and biogenesis enabling cancer immunotherapeutic responses. J Exp Med. 2018-04-02;215(4):1091-1100. doi: 10.1084/jem.20171068. nihFormattedCitation: Menk AV, Scharping NE, Rivadeneira DB, Calderon MJ, Watson MJ, Dunstane D, Watkins SC, Delgoffe GM. 4-1BB costimulation induces T cell mitochondrial function and biogenesis enabling cancer immunotherapeutic responses. J Exp Med. 2018;215(4):1091-1100. PMCID: PMC5881463.. PubMed PMID: 29511066; PMCID: PMC5881463.
Finn OJ. The dawn of vaccines for cancer prevention. Nat Rev Immunol. 2018-03-01;18(3):183-194. doi: 10.1038/nri.2017.140. nihFormattedCitation: Finn OJ. The dawn of vaccines for cancer prevention. Nat Rev Immunol. 2018;18(3):183-194.. PubMed PMID: 29279613.
Luo W, Weisel F, Shlomchik MJ. B Cell Receptor and CD40 Signaling Are Rewired for Synergistic Induction of the c-Myc Transcription Factor in Germinal Center B Cells. Immunity. 2018-02-20;48(2):313-326.e5. doi: 10.1016/j.immuni.2018.01.008. nihFormattedCitation: Luo W, Weisel F, Shlomchik MJ. B Cell Receptor and CD40 Signaling Are Rewired for Synergistic Induction of the c-Myc Transcription Factor in Germinal Center B Cells. Immunity. 2018;48(2):313-326.e5. PMCID: PMC5821563.. PubMed PMID: 29396161; PMCID: PMC5821563.
Liu A, Chen M, Kumar R, Stefanovic-Racic M, O'Doherty RM, Ding Y, Jahnen-Dechent W, Borghesi L. Bone marrow lympho-myeloid malfunction in obesity requires precursor cell-autonomous TLR4. Nat Commun. 2018-02-16;9(1):708. doi: 10.1038/s41467-018-03145-8. nihFormattedCitation: Liu A, Chen M, Kumar R, Stefanovic-Racic M, O'Doherty RM, Ding Y, Jahnen-Dechent W, Borghesi L. Bone marrow lympho-myeloid malfunction in obesity requires precursor cell-autonomous TLR4. Nat Commun. 2018;9(1):708. PMCID: PMC5816016.. PubMed PMID: 29453396; PMCID: PMC5816016.
Theodoraki MN, Yerneni SS, Hoffmann TK, Gooding WE, Whiteside TL. Clinical Significance of PD-L1(+) Exosomes in Plasma of Head and Neck Cancer Patients. Clin Cancer Res. 2018-02-15;24(4):896-905. doi: 10.1158/1078-0432.CCR-17-2664. nihFormattedCitation: Theodoraki MN, Yerneni SS, Hoffmann TK, Gooding WE, Whiteside TL. Clinical Significance of PD-L1(+) Exosomes in Plasma of Head and Neck Cancer Patients. Clin Cancer Res. 2018;24(4):896-905. PMCID: PMC6126905.. PubMed PMID: 29233903; PMCID: PMC6126905.
Whiteside TL. Head and Neck Carcinoma Immunotherapy: Facts and Hopes. Clin Cancer Res. 2018-01-01;24(1):6-13. doi: 10.1158/1078-0432.CCR-17-1261. nihFormattedCitation: Whiteside TL. Head and Neck Carcinoma Immunotherapy: Facts and Hopes. Clin Cancer Res. 2018;24(1):6-13. PMCID: PMC5754223.. PubMed PMID: 28751445; PMCID: PMC5754223.
Shayan G, Kansy BA, Gibson SP, Srivastava RM, Bryan JK, Bauman JE, Ohr J, Kim S, Duvvuri U, Clump DA, Heron DE, Johnson JT, Hershberg RM, Ferris RL. Phase Ib Study of Immune Biomarker Modulation with Neoadjuvant Cetuximab and TLR8 Stimulation in Head and Neck Cancer to Overcome Suppressive Myeloid Signals. Clin Cancer Res. 2018-01-01;24(1):62-72. doi: 10.1158/1078-0432.CCR-17-0357. nihFormattedCitation: Shayan G, Kansy BA, Gibson SP, Srivastava RM, Bryan JK, Bauman JE, Ohr J, Kim S, Duvvuri U, Clump DA, Heron DE, Johnson JT, Hershberg RM, Ferris RL. Phase Ib Study of Immune Biomarker Modulation with Neoadjuvant Cetuximab and TLR8 Stimulation in Head and Neck Cancer to Overcome Suppressive Myeloid Signals. Clin Cancer Res. 2018;24(1):62-72. PMCID: PMC5754237.. PubMed PMID: 29061643; PMCID: PMC5754237.
Kansy BA, Concha-Benavente F, Srivastava RM, Jie HB, Shayan G, Lei Y, Moskovitz J, Moy J, Li J, Brandau S, Lang S, Schmitt NC, Freeman GJ, Gooding WE, Clump DA, Ferris RL. PD-1 Status in CD8(+) T Cells Associates with Survival and Anti-PD-1 Therapeutic Outcomes in Head and Neck Cancer. Cancer Res. 2017-11-15;77(22):6353-6364. doi: 10.1158/0008-5472.CAN-16-3167. nihFormattedCitation: Kansy BA, Concha-Benavente F, Srivastava RM, Jie HB, Shayan G, Lei Y, Moskovitz J, Moy J, Li J, Brandau S, Lang S, Schmitt NC, Freeman GJ, Gooding WE, Clump DA, Ferris RL. PD-1 Status in CD8(+) T Cells Associates with Survival and Anti-PD-1 Therapeutic Outcomes in Head and Neck Cancer. Cancer Res. 2017;77(22):6353-6364. PMCID: PMC5690836.. PubMed PMID: 28904066; PMCID: PMC5690836.
Kashani-Sabet M, Nosrati M, Miller JR 3rd, Sagebiel RW, Leong SPL, Lesniak A, Tong S, Lee SJ, Kirkwood JM. Prospective Validation of Molecular Prognostic Markers in Cutaneous Melanoma: A Correlative Analysis of E1690. Clin Cancer Res. 2017-11-15;23(22):6888-6892. doi: 10.1158/1078-0432.CCR-17-1317. nihFormattedCitation: Kashani-Sabet M, Nosrati M, Miller JR 3rd, Sagebiel RW, Leong SPL, Lesniak A, Tong S, Lee SJ, Kirkwood JM. Prospective Validation of Molecular Prognostic Markers in Cutaneous Melanoma: A Correlative Analysis of E1690. Clin Cancer Res. 2017;23(22):6888-6892. PMCID: PMC5690823.. PubMed PMID: 28790109; PMCID: PMC5690823.
Davar D, Ding F, Saul M, Sander C, Tarhini AA, Kirkwood JM, Tawbi HA. High-dose interleukin-2 (HD IL-2) for advanced melanoma: a single center experience from the University of Pittsburgh Cancer Institute. J Immunother Cancer. 2017-09-19;5(1):74. doi: 10.1186/s40425-017-0279-5. nihFormattedCitation: Davar D, Ding F, Saul M, Sander C, Tarhini AA, Kirkwood JM, Tawbi HA. High-dose interleukin-2 (HD IL-2) for advanced melanoma: a single center experience from the University of Pittsburgh Cancer Institute. J Immunother Cancer. 2017;5(1):74. PMCID: PMC5604296.. PubMed PMID: 28923120; PMCID: PMC5604296.
Benedict Á, Ambavane A, Tarhini A. Comprehensive Reporting in Cost-Effectiveness Modeling. J Clin Oncol. 2017-09-10;35(26):3085-3086. doi: 10.1200/JCO.2017.73.6355. nihFormattedCitation: Benedict Á, Ambavane A, Tarhini A. Comprehensive Reporting in Cost-Effectiveness Modeling. J Clin Oncol. 2017;35(26):3085-3086.. PubMed PMID: 28715247.
Butterfield LH, Zhao F, Lee S, Tarhini AA, Margolin KA, White RL, Atkins MB, Cohen GI, Whiteside TL, Kirkwood JM, Lawson DH. Immune Correlates of GM-CSF and Melanoma Peptide Vaccination in a Randomized Trial for the Adjuvant Therapy of Resected High-Risk Melanoma (E4697). Clin Cancer Res. 2017-09-01;23(17):5034-5043. doi: 10.1158/1078-0432.CCR-16-3016. nihFormattedCitation: Butterfield LH, Zhao F, Lee S, Tarhini AA, Margolin KA, White RL, Atkins MB, Cohen GI, Whiteside TL, Kirkwood JM, Lawson DH. Immune Correlates of GM-CSF and Melanoma Peptide Vaccination in a Randomized Trial for the Adjuvant Therapy of Resected High-Risk Melanoma (E4697). Clin Cancer Res. 2017;23(17):5034-5043. PMCID: PMC5581724.. PubMed PMID: 28536308; PMCID: PMC5581724.
Ludwig S, Floros T, Theodoraki MN, Hong CS, Jackson EK, Lang S, Whiteside TL. Suppression of Lymphocyte Functions by Plasma Exosomes Correlates with Disease Activity in Patients with Head and Neck Cancer. Clin Cancer Res. 2017-08-15;23(16):4843-4854. doi: 10.1158/1078-0432.CCR-16-2819. nihFormattedCitation: Ludwig S, Floros T, Theodoraki MN, Hong CS, Jackson EK, Lang S, Whiteside TL. Suppression of Lymphocyte Functions by Plasma Exosomes Correlates with Disease Activity in Patients with Head and Neck Cancer. Clin Cancer Res. 2017;23(16):4843-4854. PMCID: PMC5559308.. PubMed PMID: 28400428; PMCID: PMC5559308.
Ferris LK, Saul MI, Lin Y, Ding F, Weinstock MA, Geller AC, Yuan JM, Neuren E, Maddukuri S, Solano FX, Kirkwood JM. A Large Skin Cancer Screening Quality Initiative: Description and First-Year Outcomes. JAMA Oncol. 2017-08-01;3(8):1112-1115. doi: 10.1001/jamaoncol.2016.6779. nihFormattedCitation: Ferris LK, Saul MI, Lin Y, Ding F, Weinstock MA, Geller AC, Yuan JM, Neuren E, Maddukuri S, Solano FX, Kirkwood JM. A Large Skin Cancer Screening Quality Initiative: Description and First-Year Outcomes. JAMA Oncol. 2017;3(8):1112-1115. PMCID: PMC5552417.. PubMed PMID: 28241191; PMCID: PMC5552417.